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ABSTRACT 
INTRODUCTION: 
Uterine cervical cancer is the most common cancer cause of death in the developing 
countries. Human papilloma virus (HPV) infection is the most important risk factor for 
cervical intraepithelial neoplasms and invasive cervical cancer. HPV oncogene expression 
and evidence of its deregulation can be monitored through direct detection of the cellular 
protein p16.p16 (INK4a) immunostaining shows great promise as a marker of lesions 
associated with high-risk HPV, and it may assist in improving the reproducibility of 
diagnoses in cervical dysplastic and reactive lesions. 
AIM AND OBJECTIVES: 
To determine the incidence,age distribution, histopathological features of uterine cervical 
neoplasms and observe the frequency and distribution of p16INK4a protein expression as a 
diagnostic marker in uterine cervical neoplasms using immunohistochemical staining and 
relating its expression with the different histological grades of uterine cervical neoplasms. 
MATERIALS AND METHODS: 
This prospective study, analyses 608 cases of uterine cervical neoplasms diagnosed in 
Thanjavur medical college during the one year period from January 2013 to December 
2013.Among which 60 cases of uterine cervical lesions selected randomly for p16INK4a 
immunohistochemical expression by immunoperoxidase method. 
RESULTS: 
• Uterine cervical neoplasms accounts for 19% of total number of cervical biopsies.The 
mean age for cervical intraepithelial neoplasms is 39.8 years and cervical carcinoma 
is 52.61 years.  
• CIN 1 constitutes majority (77%) of total cervical intraepithelial neoplasms 
cases.Squamous cell carcinoma constitutes themost common subtype (95.8%) in the 
total cervical carcinoma cases. 
• p16ink4aimmunoreactivity waspositive in 100% of all cervical neoplasms cases 
included in the study (p<0.0001) and increasing intensity of staining & percentage of 
positive tumour cells with increasing grades of cervical neoplasms. 
CONCLUSIONS: 
The pattern of over expression demonstrates the potential use of p16 as a diagnostic marker 
for cervical squamous and glandular neoplastic lesions.  
Key words: Cervical neoplasms, Human papilloma virus and p16INK4a . 
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INTRODUCTION 
 
“Cervical cancer can have devastating effects with a very high human, social, 
and economic cost, affecting women in their prime”1 
Tamilnadu Health system project (TNHSP) stated that cervical cancer kills 
women every one in seven minutes in India and in general cervical cancer is the 
prominent cancer among 30 to 60 years of age in women. In the same project, 
especially in the rural areas it is stated that cervical cancer is the leading cancer among 
women. Eighty percent of them are in low socio economic status and are at risk due to 
lack of awareness about the services available to eradicate this cancer.2 From this 
publication, it is estimated every year 132082 cases of cervical cancer were diagnosed 
in women and 74118 died due to this cancer in India.21 
As stated in TNHSP, Cervical cancer preventive measures, early diagnosis 
and remedial therapies influences on mortality rates are well documented when 
compared with other cancer. Earlier publications stated that developed countries have 
reduced cervical cancer incidence with aid of Papanicolaou smear screening 
programme. It also stated that in developing countries, cervical cancer has high 
mortality rate due to lack of proper screening methods and health infrastructure for 
routine screening. 
Cervical Cancer Screen Project, Tamilnadu Health System Project: Since 
cervical cancer has a window period of 10 to 15 years for progression of precancerous 
period to cancer, this gives an ample period for detection and treatment. In Tamilnadu 
(India), cervical cancer screening project was started on February 2007 and Tamilnadu 
Health system project experts developed a screening protocol for cancer cervix. These 
were scrutinized by Tata Memorial Cancer Institute, Mumbai and peer reviewed by 
Madurai Medical College Institutional Board, Madurai. Theni and Thanjavur districts 
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in Tamilnadu were selected as pilots for this screening due to high proportion of rural 
population. This cancer screening programme ongoing in 58 Primary Health Centres, 
13 Government Hospitals and 1 Government Medical College and Hospital in 
Thanjavur District. In this programme, women were screened between 30 to 60 years 
for Cancer Cervix using Visual Inspection Method (VIA /VILI). If positive, biopsy 
done under colposcopy and specimen sent for Histopathological examination. 
Histopathological diagnosis is considered as “gold standard” method for 
diagnosis of cervical neoplasms. However due to interobserver variability this 
diagnosis still deemed to consider an element of risk. These limitations highlight the 
need to identify the biomarkers for dysplastic epithelial cells to assist in primary 
screening and lesion diagnosis. Wide range of biomarkers are currently been evaluated 
by many studies and researchers for its diagnostic effectiveness of cervical cancer and 
its precursors. Potential biomarker should distinguish between cervical 
intraepithelial neoplasms (CIN) and other non-neoplastic cervical lesions to avoid 
any under treatment (Al Nafussi et al., 1990) or over treatment (Creagh et al., 
1995). 
An infectious agent (HPV) is being a prime cause for cervical carcinogenesis, 
detection of HPV is done by using immunomarker p16INK4a, a surrogate marker of 
HPV in immunohistochemical staining method. p16INK4a is expressed only in dysplastic 
cervical epithelial cells and is associated with high-risk HPV. In order to evaluate the 
usefulness of potential biomarker for Cervical neoplasm diagnosis, this study used 
p16INK4a biomarker in immunohistochemical staining as diagnostic marker to show the 
varied intensity and expression in uterine cervical neoplasms, which was diagnosed 
during one year period of  2013 under Pilot screening project of cervical cancers at 
TMCH. 
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AIM OF THE STUDY 
 
1. To determine the incidence of uterine cervical neoplasms in our institution 
during the one year period from January 2013 to December 2013. 
2. To evaluate the age distribution of uterine cervical neoplasms. 
3. To determine the histopathological features of uterine cervical neoplasms. 
4. To observe the frequency and distribution of p16INK4a protein expression as a 
diagnostic marker in uterine cervical neoplasms using immuno histochemical 
staining and relating its expression with the different histological grades of 
uterine cervical neoplasms. 
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MATERIALS AND METHODS 
 This is a prospective study, done to analyse the uterine cervical neoplasms for a 
period of 1 year, i.e. from January 2013 to December 2013 in the Department of 
Pathology, TMCH (Thanjavur Medical College Hospital), where Pilot Project for 
Screening of Cervical Cancer programme for cervical cancer is an ongoing process. 
Local Ethical clearance was obtained from TMCH Ethical Review committee. 
3.1 INCLUSION CRITERIA: 
o Females after the age of menarche 
o Family history of cervical cancer 
o VIA/VILI positive 
3.2 EXCLUSION CRITERIA: 
o Inflammatory lesions and any other benign lesions were excluded. 
o HPV vaccinated patient and patient on chemotherapy and radiotherapy 
o Hysterectomy specimens were excluded.  
3.3 SAMPLE SIZE: 
A total of 3198 cervical biopsies were received, diagnosed and reported 
during the study period. 608 cases of which diagnosed as uterine cervical neoplasms 
were taken as the sample size. 
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3.4 METHODS OF COLLECTION OF DATA: 
Patients clinical information,  demographic data, socio economic history, 
VIA/VILI positivity and abnormal colposcopic findings data were collected from the 
PILOT PROJECT SCREENING proforma [ Annexure I ] .Cervical biopsies specimens 
received were either punch or wedge biopsies. 
3.5 FIXATION AND GROSSING: 
All the specimens obtained were fixed in 10% buffered formalin for a period of 
24 hours and were submitted in Toto for routine histopathological examination. 
3.6 HISTOPATHOLOGICAL STUDY OF CERVICAL NEOPLASMS: 
Formalin fixed paraffin embedded tissues were sectioned of 3-5 micron 
thickness and staining with Haematoxylin and eosin (Annexure-II) was done. The H&E 
stained slides were reviewed and the interobserver variations in diagnosing the cervical 
intraepithelial neoplasms were noted. Histologic findings like basal cell hyperplasia, 
reactive atypia were downgraded. Some cases reported as HSIL were categorized as 
CIN2 and CIN3 separately during review.  
3.7 IMMUNOHISTOCHEMISTRY: 
For Immunohistochemistry, 5µ sections of formalin fixed paraffin embedded 
tissue floated on chrom alum coated slides were utilized. After heat fixation at 37 
degree Celsius overnight and 60 degree Celsius for ten minutes, deparaffinization was 
done. The antigen retrieval was done by heat using Tris buffer. The sections were 
stained using a standard peroxidase - antiperoxidase technique. The slides were 
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incubated with primary monoclonal antibody - p16 (a mouse monoclonal anti-p16 
antibody, Fremont, CA, 94538, Biogenex, USA) for one and half hour. The chromogen 
used was DiaminoBenzidine (DAB), after incubation with secondary polymer antibody 
for 30 minutes. The slides were counterstained with haematoxylin (30 seconds to 1 
min). 
3.8 ASSESSMENT OF IMMUNOSTAINS: 
EVALUATION OF IMMUNOHISTOCHEMICAL MARKER-p16INK4a 
The immunostaining was considered positive when the nucleus and/or 
cytoplasm take chest nut brown colour. Various researchers have used different 
methods for scoring p16INK4a immunostaining, but in this study four parameters were 
considered for scoring which will eventually increase the specificity of the results, and 
the parameters are as follows:  
1. Percentage of proportion of positive tumour cells42, 43,  44, 45, 46 were graded as           
0, 1+, 2+, 3+ when 0%, 1-5%, 5-25%, >25% of tumour cell shows positivity 
respectively. 
2. Intensity of staining42, 44, 47, 48, 49was graded between 0-3 (negative - 0, weak – 
1+, moderate – 2+ and Strong – 3+). 
3. p16INK4a staining in cellular reaction patterns42, 44, 45, 49 showing only 
cytoplasmic positivity, Nucleo:cytoplasmic and Nuclear positivity. 
4. Patterns of p16INK4a staining expression within epithelium in different grades of 
CIN42, 45, 50 as Diffuse full thickness, Diffuse basal and Patchy.  
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3.9 STATISTICAL METHODS: 
Descriptive statistics were derived using mean and percentages. Fisher exact 
test and Chi square test were used to assess the association between their trends in their 
subgroups. Value < 0.05 was considered as significant p value. All statistical analysis 
was done using SPSS version -18 (Statistical Package for Social Sciences) Inc., 
Chicago, USA. 
 
3.10 LITERATURE SOURCES: 
Research papers and review articles were accessed through PubMed and 
Google /Google scholar websites. 
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REVIEW OF LITERATURE 
4.1 HISTORICAL REVIEW: 
 In 400 BC, Hippocrates, the Greek physician diagnosed warts and wrote about 
cervical carcinoma. Although he could do nothing to treat the cancer, he attempted to 
treat it with the procedure known as trachelectomy. In 25 AD, Aulus Cornelius Celsus 
identified distinct types of warts: Acrochordon (skin tags), Thymion (genital warts) and 
Myremecia (non-genital warts).28 
Aretaeus, an ancient Greek physician probably of 2nd or 3rd century BC, 
described uterine cancers as superficial and deep ulcers, which would later infiltrate the 
uterus or as a growth in uterus. He distinguished between the two lesions and 
acknowledged that the symptoms and prognosis of cancer with ulcers was the most 
negative.28 
Rigoni-Stern, a surgeon in Padua in the mid-19th century had an amateur 
interest in epidemiology. He observed that uterine cancer was rare in celibate nuns 
following his study of the death certificates of women dying due to cervical 
carcinoma.29 
 In early 20th century, as stated in previous studies epidemiologists observed 
that among female sex workers cervical carcinoma is common. In women whose 
husbands with high number of sexual partners or were regular customers of prostitutes 
as well had commonly noted and less common in Jews.29 
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 In 1976, Human papilloma virus (HPV) 16 was identified in precursor lesions 
of genital cancer by Zur Hausen, Giesmann and their co-workers and in 1985, they 
demonstrated the presence of HPV DNA in cervical carcinoma cells. These findings 
created a basis for subsequent studies, which led to the development of Gardasil and 
Cervarix, the two preventive vaccines that were approved by FDA in 2006.2 
In the prevention of cervical carcinoma, the important milestones discoveries 
were: the invention of colposcopy in 1925 by Hinselmann, the development of pap 
technique by Papanicolaou, the launch of pap screening by Papanicolaou and Traut and 
the invention of a specific spatula by Ayre in 1946 to scrape the cervix. The 
standardization of screening results by Bethesda system in 1988 and further 
improvisation in 2001 was another important achievement.29 
4.2 INCIDENCE AND PREVALENCE 
Cervical carcinoma is the fifth common tumour in human being. It ranks second 
among the cancers in women, worldwide and is the leading cancer among Indian 
women. Cervical carcinoma is the leading cause of cancer deaths in second world 
countries. Every year around 510,000 new cases occur throughout the world and 
288,000 deaths globally.30A report published in the American Cancer Society’s journal 
for clinicians says that “the vast majority of deaths due to cervical cancer occur in the 
developing world, with India contributing to 27% of its mortality.”31 
The age group affected is the productive one with the starting age group of              
30-34 years and peaking in 55-65 years. Median age of occurrence is 38 years (21-67). 
Most of the sexually active females (80%) get HPV infection in the genital tract.  
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Around 365.71 million women (>15 years) in India form the risk group for 
cervical cancer. About one lakh thirty two thousand new cases occur in India 
contributing greater than one fifth of total new cases worldwide. Around one third of 
the death due to cervical cancer throughout the world is from India (74,000 deaths 
annually). Lifetime cumulative risk for Indian female is 2.5 and it is 1.4% cumulative 
death risk from the cervical carcinoma. About seventy percent of the world’s burden 
falls in the underdeveloped countries. 
There is a drastic difference between the incidence and death rate among the 
developed and underdeveloped countries. In sub-Saharan Africa the incidence is 34.8 
per 100000 women and in North America it is 6.6 per 100000 women. The death rate is 
twenty two per lakh in Africa and only 2.5 per lakh in North America. Poor access for 
proper screening, early identification and treatment explains this difference.1 
There is significant decrease in occurrence of new cases in major cities like 
Delhi, Bengaluru, Chennai and Mumbai which is evident from the respective urban 
registries. 
Cancer cervix is still the number one cancer in India as majority of the 
population (>70%) are in rural area. In 2007 incidence is 90/708 (PBCR) and relative 5 
year survival is reported as forty eight percent. 
HBCR reveals that cervix is the most common site for cancer in Chennai and 
Bengaluru, second most common site in Trivandrum and Mumbai and third most 
common in Dibrugarh. Age of occurrence is later in Trivandrum. Around forty percent 
of patients did not get treatment in spite of having diagnosed cancer cervix. Incidence 
in 5 districts recorded higher than Chennai and of them 4/5 are from north east 
Tamilnadu and Pondicherry. 
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Each year around one lakh thirty four thousand, four hundred and twenty cases 
are estimated to occur (crude incidence rate 23.5) giving rise to 203,757 by 2025 and 
increase in death to 115,751 in 2025.32 
4.3 EMBRYOLOGY3, 4 
At the 6th week of intrauterine life, the coelomic epithelium of the mullerian 
duct invaginates and fuses to form the uterus. From coelomic epithelium, basal cells are 
derived which lines the cervix. From the basal cells, some uncommitted stem cells 
(reserve cells) in the cervix is capable of differentiate into both columnar and squamous 
epithelium. 
4.4 GROSS ANATOMY  
The term CERVIX (Latin word) means NECK. Cervix is the lower most part of 
the uterus which measures 2.5 -3 cm in length in nulliparous women. The cervical 
canal opens into vagina by an opening called external os and is continuous above with 
the cavity of the uterus through an opening called internal os. The posterior aspect of 
the cervix is covered by peritoneum of the pouch of Douglas. The cellular connective 
tissue present anterior and lateral to the supravaginal portion is the parametrium. The 
ureter runs about 1 cm lateral to the supravaginal portion. 
Arterial supply 
Uterine arteries, branches of anterior division of internal iliac artery form the 
arterial supply. Uterine artery runs medially towards cervix and runs upwards to supply 
the uterus after giving a branch in the supravaginal part which supplies the cervix.3 
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Venous drainage 
Veins from plexus along the lateral border of the uterus drains through the 
uterine, ovarian and vaginal veins into iliac veins.3 
Nerve supply 
Dense uterovaginal plexus or paracervical plexus of nerves consisting of 
visceral afferent and sympathetic efferent fibres passes to the uterus through the lateral 
cervical ligament and at the junction of cervix and body gives abundant supply to the 
cervix. 
Cervical pain fibres pass from inferior hypo gastric plexus along with pelvic 
splanchnic nerves into S2-S4 segments of spinal cord.3 
4.5 HISTOLOGY 
Cervix is made up of connective tissue, muscle and elastic fibres. The epithelial 
lining is of columnar and squamous type. Major part is formed by supportive 
connective tissue. Around fifteen percent tissue is contributed by smooth muscle and 
that too concentrated in the endocervix. Isthmus contains fifty to sixty percent smooth 
muscles acting as a sphincter but portiovaginalis almost lacks smooth muscle fibres.6 
Cervico vaginal epithelium of late foetal life 
            The original squamocolumnar junction is situated just above the external 
cervical os in foetal life which at term, changes its position, caudally to the external os, 
usually on the ectocervix or rarely on the vaginal fornix walls. 
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Anatomy of Cervical Epithelium: 
There are 3 types of epithelium seen in the cervix of adult women.1) Normally 
occurring original squamous or columnar epithelium, 2) metaplastic squamous, and 3) 
atypical one having pathological lining. 
Microscopically squamous cell line contains stratified epithelium with 5 distinct 
layers or zones. They are6, 7 
Zone 1: basal cells or stratum cylindricum.  
Zone 2: parabasal cells 
Zone 3: intermediate cells 
Zone 4: interepithelial zone or condensation zone 
Zone 5: also known as stratum corneum, representing keratinisation.6 
Columnar epithelium is found lining the endocervical glands. The cytoplasm is 
granular having mucin droplets and tall uniform basally placed nuclei. They are also 
known as picket cells. 
Pictorial representation of squamocolumnar junction  
 
 
 
Original  ‘SCJ’ Endocervical eversion Transformation zone 
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Transformation zone 
The zone where the squamous epithelium meets columnar cells is known as 
squamocolumnar junction (SCJ). Morphogenically, there are two different 
squamocolumnar junction - the original squamocolumnar junction and physiological 
squamocolumnar junction. The original one is the place where squamous cells meet the 
columnar cells of endocervix at birth. 
Overtime, the columnar epithelium gets remodelled and metaplastic squamous 
cells occupy the place of columnar cells pushing the SCJ towards external cervical os. 
This new junction is known as the physiological squamocolumnar junction. 
The region between the original and the newly formed functional 
squamocolumnar junction is known as Transformation zone. Histologically this zone 
contains metaplastic epithelium. This zone is very important because all squamous 
tumours in cervix begin in new junction and extension also depends upon the 
distribution of this zone. All over the reproductive period the movement of the 
functional junction continues making the transformation zone to lie on exposed areas. 
This makes punch biopsy a useful tool for histological diagnosis. 
Metaplastic squamous epithelium 
In around 90% of post menarche cervix, squamous metaplasia is seen most 
commonly at the transformation zone. It is a normal phenomenon taking place during 
menarche and pregnancy. This does not get converted back to columnar cells and the 
metaplasia is due to the acidic pH in the vagina.6, 7, 8 
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The Cervical Stroma 
The connective tissue stroma of cervix is mainly composed of collagen fibres 
that are dense in the region of ectocervix and loosely surround the endocervical 
glands.6, 7 Inflammatory infiltrate, suggested as an immunological response to the cell 
necrosis and regeneration associated with metaplastic change is seen deep to the 
epithelium in normal cervix particularly in the transformation zone. 6, 7 
4.6 ETIOLOGY 
Human papilloma virus 
Role of HPV in carcinoma cervix was first proposed by Dr.Harald zur Hausen 
in late 1970s. This invention fetched him a Nobel Prize in 2008.6 
HPV is linked with variety of cervical lesions from benign condyloma to 
malignant carcinoma.9 
Incidence and Prevalence14, 15, 16 
The incidence of HPV virus infections varies according to age, sexual activity, 
the number of times tested and the laboratory technique used. M. El Mzibri et al stated 
that “incidence rates, vary from about 5 per 100 000 women per year in many 
industrialized countries to more than 50 per 100 000 in some developing nations”. The 
probability rate of HPV transmission of the transmission rate from male to female per 
coital act has been estimated for genital HPVs to be between 0.4 and 0.8. 
Cervical HPV prevalence peaks at young ages on sexual initiation and 
population-based prevalence remains low across the lifespan after about the age of 30 
years. HPV prevalence curves are U-shaped characterized by high cervical HPV 
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prevalence at young ages followed by a significant decline and subsequent increase in 
prevalence beginning at different later ages. Life time risk of becoming infected with 
HPV in sexually active women is more than 50%. The greatest risk of HPV infection is 
in women aged 25 years and younger. The second peak of infection occurs after the age 
of 55 yrs.  
Morphology 3, 6, 7, 12 
HPV is a small nonenveloped DNA virus. The genome of this virus contains 3 
regions for regulation, replication, oncogenesis and capsid formation. 
HPV Life cycle 
They are host specific. HPV has a great affinity towards cervical transformation 
zone. To start they infect the basal cells through a mild abrasion. Viral receptor for 
them is not clearly identified with many proposed ones. Irrespective of the grade they 
are mostly seen as episome in the benign and premalignant lesions. In true neoplasms 
they get integrate to host genome, thus promoting oncogenesis. 
HPV subtypes14, 15 
Currently, there are 148 HPV types with 33 species. Types infecting genital 
tract are classified in to high risk and low risk types. Forty HPV types infect mucosal 
epithelium with around 12 high risk subtypes that are etiologically linked to cervical 
cancer and its immediate pre-malignant precursors. Warts in the genital tract and low 
grade dysplasia are caused by low risk strains such as HPV6 and 11. High risk 
genotypes are responsible for 95% of cervical cancers. HPV 16 and 18 are found in 
most of the carcinoma. 
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Low risk HPV subtypes – 6, 11, 42 and 44 
High risk HPV subtypes – 16,18,31,33,35,39,45,51,52,56,58,59,66,68 etc 
HPV 16 is found in around sixty percent of squamous carcinoma and HPV 18 is 
found in around fifteen percent. Either of them is found in around fifty percent of high-
grade intraepithelial lesions (CIN 3).17 
 
4.7 PATHOGENESIS OF HPV13 
HPV are epitheliotrophic. Initially they enter the basal cells via micro abrasions. 
They lie within the cells as episome for years together. E1 and E2 genes help for this 
long survival by maintaining replication. Viral multiplication depends upon the host 
environment. 
In high risk HPV types E7 protein degrades pRb and p130 proteins. It drives the 
cell in to S phase.  E6 protein helps E7 protein in its action. Both of them jointly inhibit 
p53 protein action so that it decreases apoptosis which in turn facilitate tumour growth.    
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 Integration of the high risk genome represents an important event in the 
etiopathogenisis of carcinoma cervix, closely linked to progression to carcinoma from 
intraepithelial lesions.11 
HPV infection is essential for the occurrence of dysplasia and carcinoma in 
cervix, but most of the females with HPV infection have least of these lesions. Some 
risk factors other than HPV infections play as cofactor in development of cervical 
carcinoma.1 
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4.8 RISK FACTORS3 
It includes both host and viral factors. 
1) HPV infection. 
2) Oncogenecity of virus. 
3) Immunodeficiency 
4) Co-carcinogens 
High risk group includes:  
1. Multiple sexual partners. 
2. Male partner with multiple previous or current sexual partners. 
3. Young age at first intercourse. 
4. High parity. 
5. Persistent infection with a high oncogenic risk HPV. 
6. Immunosuppression. 
7. Certain HLA subtypes. 
8. Use of oral contraceptives. 
9. Use of nicotine. 
HPV prevalence increases at young ages and then remains constant with 
increasing age.  However, the second peak occurs at old age 
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Factors contributing to these age-specific regional HPV prevalence differences at 
older ages are 
• Continuing new sexual exposures. 
• Reappearance of quiescent/latent HPV. 
• Changes in immune status, such as decline in immune function and hormonal 
milieu at older ages or immunosuppression caused by coinfection with other 
viral or parasitic agents. 
• Cofactors including the cervicovaginal microbiota and pH or factors yet to be 
determined. 
 In the first 2 instances, region-specific and age-specific patterns of sexual 
behaviour would be expected to contribute to the differences in HPV prevalence. 
While, in the third and fourth instances, changes in immune responsiveness and the 
local microenvironment could modify the risk of acquisition of new HPV infection, 
activation of previously acquired but quiescent or latent HPV infections, which lead to 
persistence of both. 
4.9  WHO CLASSIFICATION OF CERVICAL NEOPLASMS (ANNEXURE IV)  
4.10 CERVICAL INTRAEPITHELIAL NEOPLASIA 
Sir John Williams in 1886 was the first to report non-invasive intraepithelial 
lesions nearer to the invasive squamous ones in the cervix. Various classification 
systems have been evolved later to describe these preinvasive cervical squamous 
lesions. 
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Initial classification used the degree of dysplasia and development of in situ 
carcinoma as severe degree. Richard used the term intraepithelial neoplasia and it is 
now used in WHO classifications. Bethasda classified them in to low grade and high 
grade lesion (table no-1). 
CIN lesions shall remain non-invasive for more than two decades shedding 
dysplastic cells that can be identified by cytology. These lesions not always progress to 
invasive one but can regress to lower grade on their own. HPV infection always co-
exists with these lesions and the types vary according to the grade as discussed 
elsewhere. They always occur in the epithelial junction and the differentiation pattern 
may reflect the differentiation “plasticity” of the transformation zone. 
TABLE NO - 1 
DIFFERENT TERMINOLOGIES USED IN VARIOUS CLASSIFICATIONS 
 
 
 
 
Old classification-1950. 
Dysplasia/carcinoma in 
situ 
Richart -1960/WHO 
classification-2008 
Bethasda system 
terminology-1988 
Mild dysplasia CIN1 LSIL 
Moderate dysplasia CIN2 HSIL 
Severe 
dysplasia/carcinoma in 
situ 
CIN3 HSIL 
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When assessing CIN lesions, the histological features to be taken into account 
are: 6, 7, 18 
1) Differentiation (maturation, stratification) 
a) Presence or absence 
b) Proportion of epithelium showing differentiation 
2) Nuclear abnormalities  
a)        Nucleus: cytoplasm ratio 
b) Hyperchromasia 
c) Nuclear pleomorphism and anisokaryosis 
3) Mitotic activity 
a) Number of mitotic figures  
b) Height in epithelium 
c) Abnormal configuration. 
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HISTOGENESIS OF CERVICAL SQUAMOUS NEOPLASIA7 
 
The grades of CIN may be characterised as follows3, 4, 18 
CIN1 
Abnormal cells are limited to lower 1/3rd of the epithelium, though slight nuclear atypia 
persist up to the surface, representing a delay in nuclear maturation. 
Nuclear abnormalities are slight and more marked in the basal third. 
Koilocytotic atypia or Koilocytosis 
 Koilos  is a Greek word, meaning  holes.25  
 It is pathognomonic of a productive HPV infection.  
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 The cellular changes presumably reflect the impact of replicating virus on the 
cells including cell cycle stimulation by the viral proteins.13 
 Differential diagnosis includes inflammatory atypia and reparative changes. 
CIN2 
Here abnormal cells are present up to ½ of the epithelial area. Atypia in the 
nucleus may extend until the surface. Increased mitotic activity is limited to the basal 
2/3rd of the epithelial lining.  
CIN3 
Immature cells extend up to or more than lower 2/3rd of the cell column. Almost 
all of the epithelium has abnormalities in the nucleus. Increased mitotic activities are 
seen at all levels. 
Understanding mainly HPV types 16 and 18 and a minority of other types are 
identified in CIN and that the greatest risk of progression is strongly associated with 
higher-grade lesions—the pathologist can appreciate that most lesions falling between 
the limits of “suggestive of LSIL” to moderate dysplasia (CIN 2) impose little 
immediate risk to the patient, a realization that will progressively diminish the 
frequency of cone or LEEP biopsy.13 
Most of the new HPV infections are self-limited and are cleared spontaneously. 
Around seventy percent gets cleared by one year and ninety percent by two years. High 
risk types take long time than the lower one for clearance. The clearance rate of HPV 
infections also decrease with time. In women with CIN1, clearance rate of HPV is up to 
seventy to ninety percent as compared to forty percent with CIN2. 
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The following table no-2 shows the metaanalysis of population based on 
cervical cancer progression from cervical dysplasia. Here, CIN 3 has a higher risk to 
get into invasive cancer.  
TABLE NO - 2 
Grade of CIN and Risk of Progression over Life Time: metaanalysis14 
 
PROGRESSION MODEL OF CERVICAL CARCINOGENESIS 
The high risk HPV infection namely HPV-16 and HPV -18 get integrated into 
the genome of human. Then there is a dysregulation of cell cycle leading to the 
uninterrupted proliferation of malignant cells. The following schematic diagram 
encloses the entire three elements which plays a major role of cervical carcinogenesis. 
The progression and regression depends mainly on the virulence of strains and 
immunological genetic factors of host. 
Degree of 
CIN 
Risk of persistent 
HPV 
Risk of progression 
to CIN3 
Risk of progression to 
cervical cancer 
CIN 1 30% 10% 1% 
CIN 2 40% 20% 5% 
CIN 3 n/a n/a 12% 
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PROGRESSION MODEL OF CERVICAL CARCINOGENESIS 
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4.11 SQUAMOUS CELL CARCINOMA18, 88, 89, 94, 95 
Squamous cell carcinoma is the most common carcinoma of cervix which 
constitutes 80-90% of total carcinoma of cervix. Nowadays frequencies have been 
reduced in developed countries due to early detection, whereas adenocarcinoma of 
cervix incidence is in increasing mode. 
The peak age of presentation to the OPD (outpatient department) is 60-64 years. 
 Clinical features – most common complaint is abnormal vaginal bleeding after 
intercourse, chronic pelvic pain and chronic illness symptoms like weight loss and loss 
of appetite. 
Gross features - tumour grow either as exophytic with papillary/ polypoid 
excrescences or endophytic with ulceroinfiltrative/nodulo-infiltrative. 
Wentz and Reagan (1958) classified SCC into three types-LCKSCC, 
LCNKSCC AND SCNKSCC. Immunohistochemistry and electron microscopy pictures 
revealed that, the term Small cell carcinoma includes Small cell neuroendocrine 
carcinoma, Small cell anaplastic carcinoma and Small cell squamous cell carcinoma. 
Nowadays the term “Small cell carcinoma” is many used for neuroendocrine 
neoplasms. 
Numerous systems for histologic grading have been proposed, based on the type 
and the degree of predominant cell differentiation, modified Broder’s classification is 
used commonly for grading the squamous cell carcinoma of cervix (table no-3). 
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TABLE NO - 3 
GRADING OF SQUAMOUS CELL CARCINOMA 
Grade of 
conventional 
SCC 
Amount of keratin Degree of 
nuclear 
atypia 
Mitotic 
figures 
Grade 1 Abundant intercellular bridges, keratin 
pearls and cytoplasmic keratinization 
Mild atypia <2/hpf 
Grade 2 Individual cell keratinization  Moderate 
atypia 
4/hpf 
Grade 3 Cells are immature, little evidence of 
squamous differentiation, cytoplasm is 
scant. 
Marked atypia >4/hpf 
 
SQUAMOUS CELL CARCINOMA (NOS TYPE) 
Microscopic features of SCC composed of varying pattern of growth, type of 
cell and differentiation. Malignant cells infiltrate the stroma with anastomosing cord 
and bands, looks like irregular islands. Necrosis may be present and it mostly of 
comedo type. SCC with micro invasive type is classified based on infiltration of tumour 
cell in the stroma by FIGO classifications. Here, invasive malignant cells have tongue 
like contour in the invading stroma. 
To say invasion of SCC in the stroma, any one of the following features should be 
present. 
• Nest of malignant cells is present near the blood vessel. 
• Presence of desmoplastic reaction in the stroma. 
• Malignant cell nest shows loss of polarity and comeodo necrosis. 
• Tongue like projection of tumour cells extending deeper with adjacent 
endocervical gland. 
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• Nest of malignant cells with features of abundant eosinophilic cytoplasm within 
the stroma. 
• Reduplication of epithelium.  
 LARGE CELL KERATINIZING SQUAMOUS CELL CARCINOMA  
To diagnosis this tumour presence of keratin pearl is must. The pearl comprise 
concentric whorls of squamous cell with central nest of acellular keratin. Individual 
tumour cells are large mature with abundant eosinophilic cytoplasm, pleomorphic 
nuclei and prominent intercellular bridges. Less frequently mitosis is seen.  
LARGE CELL NON KERATINIZING SQUAMOUS CELL CARCINOMA 
Absence of keratin pearl, increased cytological and nuclear pleomorphism and 
increased mitotic activity is the diagnosing features used to differentiate it from large 
cell keratinizing squamous cell carcinoma.  
BASALOID SQUAMOUS CELL CARCINOMA 
It is a very aggressive tumour composed of nest of basaloid squamous cell with 
peripheral palisading. Some nests shows keratinization in the centre of nest. 
VERRUCOUS SQUAMOUS CELL CARCINOMA 
This is a rare tumour and it is caused mostly by HPV 6 infection. It has an 
indolent nature and local recurrence. Tumour present with warty and exophytic growth. 
Microscopically, tumour shows large ‘bulbous’ rete pegs, surface epithelium are 
hyperplastic and hyperkeratotic. Individual squamous cell with low mitotic activity at 
the basal are arranged in a papillary process. 
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WARTY CARCINOMA 
It is also known as ‘condylomatous squamous cell carcinoma’. It associated 
with high HR-HPV infection. 
PAPILLARY SQUAMOUS CELL CARCINOMA 
The tumour present as papillary growth. Microscopically, the tumour malignant 
cells arranged are perpendicular to the fibrovascular core. The malignant cells shows 
moderate to severe dysplasia. Differential diagnosis includes warty carcinoma, 
verrucous carcinoma and squamous transitional growth. 
LYMPHOEPITHELIOMA-LIKE CARCINOMA 
This is a rare neoplasms caused by EBV infection. Microscopically, tumour 
cells are arranged in a syncytial pattern, large cells with indistinct cell borders, and 
vesicular nuclei with prominent nucleoli. Inflammatory infiltrate mainly T-lymphocyte 
obscure the background. Its histologic feature is similar to that nasopharyngeal 
carcinoma, this tumour may have favourable prognosis. 
SQUAMOTRANSITIONAL CARCINOMA 
It is important to differentiate it from transitional cell carcinoma deposit by 
detecting strain of HPV 16 and allelic loss in chromosome 3q. Histologically, 
malignant cell gets differentiate into both squamous and transitional malignant cells 
arranged over the papillary core. Since this tumour is aggressive, care should be taken 
while diagnosing it from the biopsy material. 
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SPINDLE CELL CARCINOMA 
It is a rare variant composed of malignant spindle cells arranged in the fascicles 
with foci of squamous differentiation. IHC shows positivity to epithelial markers. 
4.12 ADENOCARCINOMA OF CERVIX18, 88, 89, 95, 96 
The incidence of adenocarcinoma is in increasing mode from 5% to 15 % in 
recent decades. Cytological diagnosis of adenocarcinoma is still being challenge. The 
age of incidence is 50-55 years; the commonest cause for adenocarcinoma is HPV 
infection mainly due to 16 and 18 strains. Apart from HPV infection, oestrogen 
hormonal dysregulation have been implicated in association with adenocarcinoma 
occurrence. 
80% of cervical adenocarcinomas are mucinous adenocarcinoma, of which 
endocervical subtype is common. 
Grossly – present as ulcerative or exophytic growth. 
ADENOCARCINOMA IN SITU 
ACIS was first described in 1953, and its frequency has been increasing steadily 
since then. 
Christopherson WM et al described the average age of presentation as 35 to 40 
years, approximately 10 years earlier than invasive adenocarcinoma;39More than 90% 
of cases of adenocarcinoma and ACIS have detectable HPV. 
Boon ME et al. stated that individual cases of ACIS have been observed to 
progress towards invasive adenocarcinoma and that ACIS is usually present adjacent to 
most very early invasive adenocarcinomas.38 
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Bertrand M et al described that ACIS arises either from columnar epithelium or, 
more likely, from reserve cells that have the capacity to undergo columnar cell 
differentiation. Evidence for the role of reserve cells is the common coexistence of 
ACIS with HSIL and its frequent location near the squamocolumnar junction. The 
lesion may arise on the surface, followed by extension into crypts and replacement of 
normal mucosa.40 
Histologically, the lining epithelium is stratified and crowded, and consists of 
moderately enlarged nuclei with coarse chromatin. Mitotic figures are easily found, 
often suspended on or near the luminal surface of the gland and are essential to the 
diagnosis. Nucleoli are usually small and inconspicuous, but prominent in some cases. 
A periglandular inflammatory reaction may be present. Apoptotic bodies, present in 
80% of cases. Uncommonly, ACIS will mimic a reactive epithelial process, with 
prominent multinucleation. So any columnar cell atypia should be carefully evaluated. 
The most common subtype of ACIS is the endocervical type. Other subtypes are 
the Endometrioid pattern and the Intestinal type.13 
GRADING OF ADENOCARCINOMA37 
Cervical adenocarcinoma is graded based on two factors which include the 
pattern (% of solid growth) and cytological nuclear feature. It has been graded in to 
three grades from 1to 3. Grade 1 is well differentiated, grade 2 is moderately 
differentiated and Grade 3 is poorly differentiated. 
Grade 1 carcinoma shows following features- malignant glands are regular 
with papillae, individual columnar cells shows minimal stratification with uniform oval 
nuclei. Mitotic figures are rare. Solid growth area of atleast ≤ 10%should be present. 
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Grade 2 carcinoma shows following features- malignant glands are complex 
with bridging, nuclei become rounded and irregular with micro nucleoli. Mitotic figures 
are frequently seen and Solid growth pattern constitutes 10-50%. 
Grade 3 carcinoma shows following features - only few malignant glands are 
seen. Individual cells are large with high pleomorphism, mitotic figures are more 
common and necrosis is present. Solid pattern of growth is >50%. 
MUCINOUS ADENOCARCINOMA 
There are five types of mucinous adenocarcinoma which includes endocervical, 
intestinal, signet ring cell type, minimal deviation and villoglandular type. 
ENDOCERVICAL ADENOCARCINOMA 
CGIN is a premalignant condition. The morphological feature is characterized 
by malignant glands which are lined by tall columnar cells with hyperchromatic nuclei. 
The cells have cytoplasmic mucin which is inconspicuous. Mitotic figures are 
prominent in the luminal cells. Apoptotic bodies are seen in the dysplastic glands. The 
glands are arranged in back to back fashion with complex architecture such as 
intraluminal papillae, budding and branching patterns. Desmoplastic reaction is noted 
around the tumour cells in the stroma. Endocervical adenocarcinoma is otherwise 
called as colloid carcinoma, since the malignant cells secrete large amount of mucin 
forming lakes in the stroma. 
Different variants documented are Microcystic variant and dedifferentiated 
variant. 
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INTESTINAL VARIANT OF ADENOCARCINOMA 
This type of carcinoma resembles the morphological features of intestinal 
adenocarcinoma. This variant is uncommon. HPV infection is not associated with the 
risk factors of intestinal variant. Some foci show intestinal epithelial cells like goblet 
cells, less frequently endocrine cells and paneth cells. Necrosis is a prominent feature 
observed.  
Before diagnosing as an intestinal variant, metastasis from the intestine should 
be ruled out.  
SIGNET RING CELL VARIANT  
Pure form of signet cell carcinoma is uncommon. Both poorly differentiated 
adenocarcinoma and adenosquamous carcinoma exhibits some foci of signet ring cell 
changes. Differential diagnosis includes metastatic tumour and squamous cell 
carcinoma with signet ring cell change.   
ADENOMA MALIGNUM/ MINIMAL DEVIATION VARIANT 
 This is an uncommon tumour, the incidence being 1-3 %. This variant is 
associated with Peutz- Jeghers syndrome. Malignant glands are arranged haphazardly 
that extend beyond the normal endocervix, which shows moderate nuclear atypia and 
desmoplastic reaction. Diagnosis cannot be made out with punch biopsy, since the 
depth of penetration is the criteria. Differential diagnosis includes endocervical 
glandular hyperplasia- laminar& lobular, endocervicosis, deep seated Nabothian cyst 
and adenomyoma. In endometrioid adenocarcinoma, this variant is also seen. 
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VILLOGLANDULAR VARIANT 
This is an uncommon type, occurs in premenopausal age group which ranges 
from 33 to 39 years whose comes with the complaints of vaginal bleeding. There is an 
association with the oral contraceptives usage. Microscopic features are surface 
papillae mostly tall, thin papillae intermixed with broad short papillae. Since tumour 
have frond like arrangement which resembles villoglandular adenoma of the colon. The 
lining epithelium may be intestinal type, endocervical type and endometrioid type. It 
has a better prognosis, since there is no vascular invasion.  
ENDOMETRIOID ADENOCARCINOMA 
These tumours constitute 30% of total adenocarcinoma of cervix. 
Microscopically, the malignant cell resembles endometrial adenocarcinoma cells, but 
the differentiating point is minimal squamous metaplasia, focal cytoplasmic mucin, 
adjacent CGIN and absence of complex endometrial hyperplasia. The cells are 
columnar shape with large elongated hyperchromatic nuclei. The cells arranged in 
sheets with 2D rosettes like pattern.  Here, immunohistochemistry places the main role 
that is vimentin is more specific, positive in endometrial adenocarcinoma whereas 
diffuse positivity of p16 in cervical neoplasm.  
Differential diagnosis for adenoma malignum of endometrioid variant are, 
Endometriosis, tuboendometrioid metaplasia and endometrioid endometrial 
adenocarcinoma. 
IHC – vimentin-, CEA+, ER-, HPV in situ +, p16+.      
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CLEAR CELL ADENOCARCINOMA 
This is another uncommon tumour, constitutes about 2-4%, age of occurrence 
shows bimodal pattern. Younger age group presentation is usually associated with intra 
uterine diethylstilboestrol consumption, whereas old age presentation is not associated 
with DES exposure. Microscopically the tumour composed of clear polygonal cells 
with hobnail nuclei arranged in a papillary, tubulocystic or solid pattern. Stroma may 
be scanty. Similar morphological features are also seen in clear cell adenocarcinoma of 
ovary, vagina, and endometrium. 
The differential diagnosis includes mesonephric hyperplasia, aria stella change, 
and microglandular hyperplasia with clear cell change.   
SEROUS ADENOCARCINOMA 
It is an uncommon tumour constitutes about 3%. The age of presentation is 
bimodal type with the range from 26 to 70 years; one peak is at 45 years and other at 65 
years. Histologically, malignant cells are arranged in a complex papillary pattern with 
cellular stratification, budding and tufting. There are gland formation in solid areas and 
slit like spaces are also seen. The cells show moderate to marked nuclear atypia with 
increased mitotic figures, psammoma bodies is the characteristic feature noted. 
Histologic feature resembles the serous papillary ovarian, endometrial and peritoneal 
tumour. This tumour is very aggressive and have very poor prognosis.  
MESONEPHRIC ADENOCARCINOMA 
It arises from the mesonephric remnants; most common site is lateral wall of 
cervix. This is a rare tumour with peak age of incidence is 52 years with a range of 34 
to 84 years. Grossly it present as exophytic lesions with circumferential involvement 
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and the tumour size range from 2 to 8 cm. Microscopically, pattern of arrangement of 
malignant cells in this adenocarcinoma varies which includes retiform, solid, tubular, 
ductal and sex cord like. Most common pattern is tubular in which glands are lined by 
cuboidal epithelium with mucin free and the lumen is filled with eosinophilic hyaline 
material. 
Differential diagnosis includes Endometroid variant adenocarcinoma of cervix, 
endometrial adenocarcinoma and diffuse mesonephric hyperplasia. 
IHC- pancytokeratin+,CK7+, CAM 5.2+, EMA+, calretinin+ and vimentin+. 
CK20 and monoclonal CEA negative. 
4.13 NEUROENDOCRINE TUMOURS94, 95, 96 
WHO classifies neuroendocrine tumours into four type’s such as carcinoid, 
atypical carcinoid, small cell neuroendocrine carcinoma and large cell neuroendocrine 
carcinoma. 
SMALL CELL NEUROENDOCRINE CARCINOMA  
Incidence is 1-6% with age occurrence is similar to that age group of squamous 
cell carcinoma (21 to 87 years). Mean age is fifth decade. Most common cause is HPV 
16 and 18. Grossly, the tumour is large ulcerating mass extend up to the parametrium, 
vagina and uterus. Microscopically, tumour is highly cellular composed of solid sheets, 
trabeculae, single cells and ill-defined or with sharply outlined nests. Small rosette-like 
or acini areas are seen. Individual malignant cells are oval to spindle in shape with 
scant cytoplasm. Nucleus is hyperchromatic, moulded with salt and pepper chromatin 
and inconspicuous nucleoli.  Mitotic figures are high up to >50/ hpf. Adjacent foci of 
precancerous and cancerous lesion of both squamous and glandular type may be 
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present. The tumours typically have a delicate fibrovascular stroma. The tumour is 
aggressive and has a high propensity for metastasis. 
The cells are argyropilic and show immunoreactivity for Neuron specific 
enolase. 
Differential diagnosis includes small cell squamous cell carcinoma, lymphoma, 
and adenoid basal carcinoma. 
Classification of endocrine tumours other than small cell carcinoma of the 
uterine cervix based on mitoses, nuclear atypia and necrosis 
Typical carcinoid tumour- rare, 0-1+ and necrosis. 
Atypical carcinoid tumour-=< 10 MFs/10hpf, 1+-2+ and focal. 
Large Cell Neuroendocrine carcinoma - >10 MFs/10hpf, 2+-3+ and geographic 
necrosis. 
LARGE CELL NEUROENDOCRINE ADENOCARCINOMA 
This is a rare carcinoma, less common than small cell carcinoma. Age of 
occurrence is wide range with mean age of 34 years. Grossly, tumour is large and more 
deeply invasive than other endocrine tumour. Microscopically, the  pattern of malignant 
cells arrangement is insular, trabecular and solid with areas of geographic necrosis. 
Individual tumour cells are medium to large size with abundant cytoplasm containing 
eosinophilic granules, nucleus shows high grade and high mitotic figures >20/hpf.  
Single cell infiltration is absent in this tumour. Adenocarcinomatous differentiation is 
common. 
Differential diagnosis includes poorly differentiated squamous cell carcinoma. 
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Argyrophilia and immunoreactivity for chromogranin are present. 
4.14 OTHER EPITHELIAL TUMOURS18, 94, 95, 96 
ADENOSQUAMOUS CARCINOMA 
It is defined as tumour composed of mixture of squamous and glandular 
elements recognizable on H&E slides. Thus it should be differentiated from 
endometrioid adenocarcinoma which contains benign squamous differentiation. Signet 
ring cell type and clear cell type variant is also seen. 
Differential diagnosis includes scattered mucin containing cells in poorly 
differentiated squamous cell carcinoma. 
GLASSY CELL CARCINOMA VARIANT 
This rare tumour is a poorly differentiated adenosquamous cell carcinoma 
which accounts 1-2%. It occurs in the age group younger (30-44) than other tumour 
occurrence. Grossly, the tumour is bulky and exophytic mass measures 3 -7cm. 
microscopically, malignant neoplasm composed of sheets and nest of malignant cells. 
Individual cells are large with abundant eosinophilic cytoplasm which is ground glass 
appearance. The cell border is distinct. The nucleus is large with macro nucleoli and 
prominent mitotic figures. The stroma has plasma cell and eosinophil inflammatory 
infiltrate. It is highly aggressive tumour and unresponsive to radiotherapy.  
Differential diagnosis includes poorly differentiated squamous cell carcinoma 
and Lymphoepithelioma like carcinoma. 
IHC- low and high molecular weight keratin +, MUC-1& MUC-2+ and ER & 
PR negative. 
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ADENOID CYSTIC CARCINOMA 
Adenoid cystic carcinoma of cervix has similar histological features of salivary 
gland tumours. It occurs in the postmenopausal females with mean age of 60 years 
particularly in black women. The cell of origin is reserve cell in the cervix. Grossly, the 
tumour is either small polypoid growth to large exophytic/endophytic friable mass. 
Microscopically, malignant neoplasms composed of cribriform pattern of nest and 
cords of small basaloid cells with scant cytoplasm. Unlike salivary gland, the 
neoplasms in cervix shows marked nuclear atypia, high mitotic activity and necrosis. 
The cystic space is filled with hyaline eosinophilic secretion or basophilic mucin. The 
hyalinised stroma situated within the tumour nest contains basement membrane 
material positive for PAS. Presence of squamous intraepithelial neoplasia above the 
tumour nest is frequently observed. This tumour is aggressive and got poor prognosis. 
Differential diagnosis includes small cell Nonkeratinizing squamous cell 
carcinoma, small cell neuroendocrine carcinoma and adenoid basal carcinoma. 
IHC- MNF116, CAM 5.2 and EMA markers are positive. 
ADENOID BASAL CARCINOMA 
This is a rare neoplasm; occur in the post-menopausal females with the range 
19-91 years. The HPV DNA most commonly encountered here is HPV16 strain. Since 
adenoid basal carcinoma and adenoid cystic carcinoma has similar histiogenesis, 
microscopic features and epidemiology, it is difficult to differentiate between them. 
The main differentiating features are absence of hyaline basement material; mitosis and 
nuclear atypia are rare; it is less aggressive and never metastasized to lymph node. 
Microscopically, malignant neoplasms composed of nest of uniform basaloid cell with 
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peripheral palisading with no stromal response. It is associated with cervical 
intraepithelial neoplasms and micro invasive squamous cell carcinoma with focal 
squamous cell or glandular differentiation. Thus, it is named as ‘Epithelioma’ due to its 
benign nature and good prognosis. 
Differential diagnosis includes Adenoid cystic carcinoma, Basaloid squamous 
cell carcinoma and adenoid basal hyperplasia. 
IHC – CAM 5.2, CK7, EMA, CEA, p53 and p63 marker shows positivity.  
4.15 MESENCHYMAL TUMOURS 
This tumour incidence is very less common. Both benign and malignant 
tumours are noted in which smooth muscle tumours are the most common.  
BENIGN TUMOURS 
Leiomyoma is the most common tumour and constitute <2%. The microscopic 
feature is similar to that of uterine leiomyoma. 
Genital rhabdomyoma presents as polypoid lesions, microscopic features shows 
rhabdomyoblast with benign nature which is dispersed in the edematous and myxoid 
stroma. Cambium layer is absent. 
Other benign tumours like haemangioma, schwannoma, granular cell tumour, 
lipoma, glomus tumour, localised neurofibromatosis, ganglioneuroma and 
paragangiloma have also been reported. 
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MALIGNANT TUMOURS 
Leiomyosarcoma present as polypoid growth with soft, fleshy consistency. 
Microscopically, it is composed of interlacing bundles of smooth muscle fibres with 
marked atypia and necrosis. 
Endometrioid stromal sarcoma, low grade is a rare tumour arising from outside 
the uterus and histologic features are similar to that of uterus neoplasm.  
Undifferentiated endocervical sarcoma histologically composed of malignant 
cells with ill-defined cell borders. Individual cells are spindle to stellate shape arranged 
in a fasciculate or storiform pattern. The nucleus is hyperchromatic. 
Sarcoma botryoides has been associated with sertoli-leydig cell tumour which 
composed of individual cells with spindle, oval, small nuclei with some foci show 
differentiation to skeletal muscles. 
Alveolar soft part sarcoma present as polyp, histologic features shows 
individual cells with large epithelial like cell with eosinophilic, granular cytoplasm 
arranged in the solid or alveolar pattern. It has the better prognosis than other site.  
Other tumour includes malignant peripheral nerve sheath tumour, liposarcoma, 
osteosarcoma and malignant fibrous histiocytoma. 
4.16 MALIGNANT MIXED EPITHELIAL MESENCHYMAL TUMOURS 
Carcinosarcoma is rare neoplasms composed of both malignant epithelial 
component (squamous cell, adenoid basal carcinoma and adenoid cystic carcinoma) 
and homologous mesenchymal component. Most common strain of HPV isolated here 
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is HPV 16. Age of occurrence is in postmenopausal (61years) age group. This is a very 
aggressive tumour. 
Other malignant tumour like adenosarcoma, Wilms tumour is also reported. 
Benign neoplasms like adenofibroma, adenomyoma with variant have also 
being reported. 
HAEMATOPOIETIC LESIONS like lymphoma and leukaemia involving the cervix 
is rare.  
MELANOCYTIC LESIONS including both benign lesion like blue naevus and 
malignancy like melanoma is also reported. 
4.17 MISCELLANEOUS TUMOURS AND METASTASES 
Germ cell tumours like dermoid cyst, yolk sac tumour have also been reported. 
Other rare tumours like Ewing sarcoma and trophoblastic tumour incidence have also 
been reported. 
Metastases from breast, ovary, peritoneal and pancreas are also reported. 
 4.18 STAGING OF CERVICAL NEOPLASMS (ANNEXURE V) 
4.19  SCREENING OF CERVICAL CARCINOMA 
Most of the cervical carcinoma (around eighty percent) are identified in later 
stage leading to decreased survival rates (5yr survival< forty percent).33,34 
                The important aim of screening is to decrease the incidence and mortality of 
cervical carcinoma. Identifying pre-neoplastic stage early is an effective measure of 
reducing mortality due to carcinoma cervix.  
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Methods of screening 
               Though there are different methods of screening, the most effective has been 
Pap smear.35In 1939, Papanicolaou and Herbert Traut initiated systematic evaluation of 
vaginal smears and it became apparent that abnormal cells could be found in several of 
the asymptomatic patients.36 
The other methods used for screening are as follows35 
• Unaided visual inspection 
• Visual inspection after application of acetic acid (VIA) 
• VIA with magnification 
• Visual inspection after application of Lugol’s iodine (VILI) 
• HPV DNA testing screening 
Screening plays an important role in early detection of cervical neoplasm. Pap 
smear helps in early detection of premalignant and early cervical carcinoma. But it has 
false negative rate of about fifteen to fifty percent and false positivity rate of about 
thirty percent25 
Methods involving visual inspection 
 VIA -visual inspection with acetic acid (white vinegar) -involves the application of 
4-5% acetic acid on the cervix and  the test result is based on the colour and margin of 
the aceto-white epithelium, the surface contour, the arrangement of the blood vessels. 
VILI (Visual inspection with lugol’s iodine) - Cervical neoplasia fails to stain deeply 
with iodine due to the lack of glycogen. 
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• It is cheap and simple alternative to Pap smear. 
• Both this technique help to identify precancerous lesions by naked eye 
• There is no need for separate lab and can be used in a simple clinic setup. 
• Any trained medical and paramedical persons can be trained to perform this test.  
Dr.Shastri and colleagues initiated a randomized control trial on usage of VIA 
on large scale. They found that it decreased the mortality to eleven deaths per one lakh 
women years of observation. It amounts to thirty one percent reductions in comparison 
with the control group.  
Colposcopy 
 The colposcopy is a non-invasive binocular instrument designed to examine the 
cervix with   6 to 40-fold magnification. Most cervical neoplasia arises in the 
transformation zone, hence the relevant colposcopic signs are observed within its 
limits. 28 
Abnormal colposcopic findings include 
 white keratotic lesions apparent before the application of acetic acid , termed 
"leukoplakia"  
 aceto-white epithelium, 
 punctuation, 
 mosaic pattern, 
 Atypical tortuous vessels.         
               A variation in quality and quantity of the above atypical appearances helps to 
differentiate cervical neoplasia from physiological, benign, infective, inflammatory and 
reactive changes in the cervix. Colposcopy and histopathology are complementary to 
the diagnosis and management of CIN.18 
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p16INK4A 
p16INK4a is a promising biomarker for cervical neoplasm screening. Murphy et 
al reported a sensitivity of ninety nine percent and specificity of hundred percent.25 
Recent recommendations from ACS and ASCP also included HPV and its biomarker as 
an important screening tool. It is given as grade A recommendation. 
4.20 PROGNOSTIC MARKERS 
The prognosis of cervical carcinoma is related to the following parameters: 9 
1. Clinical stage: is the most important prognostic determinator. 
2. Nodal status: is a crucial predictor found to be an independent prognostic marker. 
3. Size of the largest involved node and number of positive nodes. 
4. Size of the primary tumour as determined by measurement of the tumour’s greatest 
diameter or by volumetric techniques. 
5. Depth of invasion. 
6. Endometrial extension: decreases the survival rate by a factor of 10-20%. 
7. Parametrial involvement detected microscopically. 
8. Blood vessel invasion. 
9. Microscopic grade: Whether the degree of tumour differentiation as evaluated in 
routinely stained sections correlated with survival independently from staging is a 
controversial issue. The two types of grading used is Reagan-Ng and Broder’s 
method.  
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10. Microscopic type: Some authors have found a better prognosis with large cell non-
keratinizing type and a worse prognosis with the small cell type but others found no 
correlation. 
11. Tumour associated tissue eosinophilia (TATE): Presence of numerous mature 
eosinophils in the inflammatory infiltrate of cervical carcinoma has been associated 
with improved survival in one study and poor survival in other. 
12. Keratin profile: No predictive value seems to be attached. 
13. Cell proliferation index: High S-phase rates as determined by flow cytometry are 
correlated with both a poorly differentiated histologic type and decreased short term 
survival. 
14. Angiogenesis: There is no evidence of a correlation between micro vessel density 
and prognosis. 
15. HPV: It has been claimed that HPV is a major determinant of the course of cervical 
cancer. 
16. Others: Stromal infiltration by S-100 protein positive Langerhans cells, allelic loss 
of chromosome 1, expression of HER2/neu, RAS oncogene and Tn antigen have all 
been found to related to an unfavourable outcome. 
4.21 BIOMARKERS  
Different classes of biomarkers are categorized at the molecular level which has a 
promising effect in diagnosing carcinoma of cervix. The markers are 
• Apoptotic markers 
• Epigenetic regulations-imaging marker, methylation and metabolic markers 
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• Cell cycle check points 
• Angiogenetic parameters 
• Chromosomal anomalies 
• Tumour suppressor gene expression 
p16INK4a 
p16INK4A gene is situated in the 9p21chromosome which transcript the cell-cycle 
inhibitor protein .i.e.CDK 4 and 6 24. It is a negative regulatory protein and product of 
CDKN2A gene. Serrano et al reported that, it regulates the progression of eukaryotic 
cells through the G1 phase of the cell cycle.16 
In normal quiescent cell, retinoblastoma protein is in active state 
(hypophosphorylated form) and it is bound to E2F (transcription factors) thus 
preventing it to regulate the progression of cell cycle. In bounded form Rb is a negative 
regulator of p16. p16 prevents the Rb protein phosphorylation by inhibiting the cyclin 
dependant kinase 4 and 6 and keeping it in active form. 
In HR-HPV infected cell, the viral transcription factors gets bind to Rb protein 
to make it inactive form. So Rb protein cannot able to inhibit the transcription of p16 
tumour suppressor protein. Thus p16 is over expressed in dysplastic cells not in the 
normal epithelium. 
Identification of biomarker p16 by IHC in dysplastic cells is an ongoing study 
all over the world to reduce the interobserver variations and to improve the 
reproducibility in diagnosing fields16, 24.  
The results of hr-HPV genotyping were compared to the expression levels of 
p16INK4a mRNA. It was determined that all HR-HPV types cause the increased 
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p16INK4a mRNA expression; however, the correlation between the particular HR-
HPV type and the p16INK4a mRNA level is obscure. This suggests that all HR-HPV 
types may dysregulate the cell cycle by a similar molecular mechanism. Therefore, it 
can be concluded that the oncogenic potential of HPV but not a particular HR-HPV 
type is the main cause of enhanced p16INK4a mRNA expression indicating the 
dysregulation of cell cycle and leading to high-grade cervical lesions.23 
Comparative study model of cell cycle mechanism both in normal cell and Hpv 
infected cell  
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Ki67/MIB-1 
A Dysplastic cell usually shows increased cell cycling. Ki67 and MIB-1 are 
markers of proliferation; they are strongly expressed in CIN lesions and normal basal 
cells that have proliferation capacity. 
MYC 
This oncogene is frequently amplified and over expressed in cervical cancer.  
Survivin 
Survivin is an another independent marker of high-risk HPV type which is an 
anti-apoptotic marker. It might be an early predictor of cervical carcinogenesis.  
Phosphatase and tensine homologue (PTEN) 
 This anti-oncogene is negatively correlated with survivin expression in CIN 
and cervical cancer.  
Telomerase 
In cervical dysplasia particularly in CIN 3, it was found that there is an 
increased telomerase activity with varying sensitivity.  
The mini chromosome maintenance (MCM) 
This is a class of proteins of the DNA pre-replication complex. Early 
publications have shown that the MCM proteins and in particular MCM5 are useful for 
detection of cervical diseases.  
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Topoisomerase II-α (TOP2A) 
Key proteins like MCM and TOP2A are expressed during this aberrant gene 
transcriptional activation which is over expressed in cervical diseases.  
 
ProExC 
It is an anti-topoisomerase II alpha antibody mainly used to distinguish 
squamous metaplasia and dysplasia. Thus it mainly helps in cytological smears. 
Aneuploidy, chromosomal imbalances 
Many studies have found that, with the integration of HPV genome with the 
human gene will lead to chromosomal imbalances mainly on the 3q chromosome, 
which is usually seen in the higher grades of CIN and also in transition to invasive 
carcinoma. 
p53 and pRB 
These are the targets of HPV oncogenes E6 and E7. Loss of p53 and pRB 
represents an indirect sign of HPV E6 and E7 expression. This loss is not specific for 
HPV and is present also in other tumours. In HPV infection, there is an inverse 
relationship with progression and frequency of pRB and p53 
Cyclins 
Are regulatory proteins involved in cell cycle regulation. A strong association 
was found between Cyclin E and HPV induced cell changes. Cyclins A and B are over 
expressed in cervical adenocarcinoma and its malignant precursors.  
Angiogenetic markers 
Obermair et al. demonstrated the angiogenetic parameters such as ‘micro vessel 
density and the expression of vascular endothelial growth factor (VEGF)’ increase with 
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the grade of CIN, Suggesting that angiogenesis might be used as a prognostic factor in 
patients with squamous cell carcinoma. 
nm23-H1 
It is a human antimetastatic gene. In carcinoma of cervix it is found that the 
levels are inversely related to cervical neoplasm grade. 
4.22 IHC-REVIEW 
Immunohistochemistry (IHC) is a technique which identifies cellular proteins 
(antigen) by its ability to bind monoclonal antibody. The importance gained by this 
method is that it identifies the reaction by light microscope. Though Coons introduced 
it before 70 years, it is widely used in the past twenty years only. The enzymatic label 
(horseradish peroxidase) developed by Avrameas and by Nakane and colleagues helps 
in identifying the labelled antibody by microscope itself.17 
In Oxford, Taylor and Burns in 1974 made IHC more useful by making it 
possible in normal paraffin embedded tissue. With this, the issue of greater sensitivity 
was raised and subsequently solved by series of development of enzymes and labelling 
systems. Now it becomes a routine to do one or more IHC stains for tumour diagnosis. 
Enzyme digestion was introduced by Hung as a pre-treatment to IHC staining to 
unmask some antigens that had been altered by formalin fixation. Enzyme digestion 
was followed by invention of antigen retrieval method (AR). In contrast to enzyme 
digestion, the AR technique is a simple method. The intensity of IHC staining was 
increased dramatically after AR pre-treatment. 
p16INK4a is a useful IHC marker with high sensitivity and specificity for cervical 
carcinoma diagnosis. 
S.NO OP NO HP NO AGE WHO CLASSIFICATION 
GRADE OF 
DIFFERENTIATION 
1 158440 3/13 45 LCNKSCC GRADE 2 
2 158427 5/13 55 LCNKSCC GRADE 2 
3 158351 11/13 59 CIN 1 NA 
4 131213 12/13 45 LCNKSCC GRADE 2 
5 144762 15/13 70 SCNKSCC GRADE 3 
6 144967 20/13 26 CIN 1 NA 
7 144057 22/13 60 LCKSCC GRADE 1 
8 144775 23/13 55 LCKSCC GRADE 1 
9 243983 29/13 70 LCKSCC GRADE 1 
10 1447121 34/13 73 SCNKSCC GRADE 3 
11 152439 37/13 70 LCNKSCC GRADE 2 
12 131164 38/13 55 LCKSCC GRADE 1 
13 1847 41/13 55 CIN 1 NA 
14 134633 44/13 30 CIN 1 NA 
15 2233 50/13 65 LCNKSCC GRADE 2 
16 2239 52/13 50 LCKSCC GRADE 1 
17 2006 54/13 30 CIN 3 NA 
18 2040 59/13 23 CIN 1 NA 
19 14934 61/13 46 CIN 2 NA 
20 149063 63/13 38 CIN 1 NA 
21 1834 66/13 30 CIN 2 NA 
22 512201 71/13 35 CIN 1 NA 
23 7290 80/13 60 ADENO SCC 
24 7298 82/13 47 LCNKSCC GRADE 2 
25 7300 85/13 50 CIN 1 NA 
26 176631 94/13 45 LCKSCC GRADE 1 
27 737 95/13 60 CIN 2 NA 
28 176626 96/13 40 LCNKSCC GRADE 2 
29 281 97/13 55 LCNKSCC GRADE 2 
30 246665 98/13 48 CIN 1 NA 
31 1819 102/13 50 LCNKSCC GRADE 2 
32 2474 104/13 50 ADENO SCC 
33 18294 115/13 60 LCNKSCC GRADE 2 
34 246664 117/13 47 LCKSCC GRADE 1 
35 2488 118/13 32 CIN 1 NA 
36 19320 120/13 45 CIN 2 NA 
37 18557 126/13 67 SCC WITH MICROINVASION 
38 140144 129/13 55 LCNKSCC GRADE 2 
39 1853 144/13 38 CIN 1 NA 
40 19366 150/13 60 LCNKSCC GRADE 2 
41 19432 151/13 40 SCNKSCC GRADE 3 
42 2317 158/13 42 CIN 2 NA 
43 23131 160/13 60 LCKSCC GRADE 1 
44 25288 162/13 43 ADENO SCC 
45 23406 171/13 68 SCNKSCC GRADE 3 
46 23427 172/13 39 CIN 1 NA 
47 24142 176/13 55 ADENOID BASAL CARCINOMA 
48 24213 183/13 37 CIN 3 NA 
49 24484 190/13 30 CIN 1 NA 
50 24284 195/13 65 LCNKSCC GRADE 2 
51 24285 198/13 51 LCNKSCC GRADE 2 
52 19554 201/13 45 LCNKSCC GRADE 2 
53 19638 202/13 26 CIN 1 NA 
54 28474 214/13 55 LCNKSCC GRADE 2 
55 23354 215/13 45 LCNKSCC GRADE 2 
56 28286 216/13 55 CIN 1 NA 
57 10180 218/13 38 LCNKSCC GRADE 2 
58 28331 219/13 60 LCNKSCC GRADE 2 
59 28210 220/13 34 CIN 1 NA 
60 24933 221/13 43 CIN 1 NA 
61 28212 223/13 53 LCNKSCC GRADE 2 
62 1437668 224/13 60 LCNKSCC GRADE 2 
63 28177 225/13 50 LCNKSCC GRADE 2 
64 201844 227/13 27 CIN 2 NA 
65 19941 228/13 75 LCNKSCC GRADE 2 
66 19999 229/13 30 CIN 1 NA 
67 19917 235/13 38 CIN 2 NA 
68 19838 236/13 37 LCNKSCC GRADE 2 
69 18985 241/13 40 CIN 2 NA 
70 28107 242/13 45 CIN 3 NA 
71 28112 245/13 28 CIN 1 NA 
72 19841 247/13 51 CIN 1 NA 
73 222606 249/13 40 CIN 1 NA 
74 18273 258/13 47 LCNKSCC GRADE 2 
75 28682 261/13 55 LCNKSCC GRADE 2 
76 28924 268/13 38 LCNKSCC GRADE 2 
77 28904 273/13 58 LCNKSCC GRADE 2 
78 28121 275/13 55 LCNKSCC GRADE 2 
79 258181 276/13 65 LCNKSCC GRADE 2 
80 2886 277/13 44 LCNKSCC GRADE 2 
81 28899 278/13 34 CIN 2 NA 
82 27558 287/13 45 LCNKSCC GRADE 2 
83 24158 288/13 70 LCNKSCC GRADE 2 
84 78889 289/13 50 CIN 2 NA 
85 27603 296/13 40 LCNKSCC GRADE 2 
86 1439751 297/13 55 LCKSCC GRADE 1 
87 27657 303/13 35 CIN 3 NA 
88 27902 318/13 37 LCKSCC GRADE 1 
89 41085 319/13 55 LCNKSCC GRADE 2 
90 24156 321/13 45 SCNKSCC GRADE 3 
91 7433 324/13 33 CIN 1 NA 
92 4114 326/13 29 CIN 1 NA 
93 41100 328/13 37 CIN 1 NA 
94 41183 329/13 55 CIN 3 NA 
95 41111 331/13 38 CIN 1 NA 
96 41091 334/13 45 CIN 1 NA 
97 41245 337/13 65 LCKSCC GRADE 1 
98 1276 338/13 40 CIN 3 NA 
99 412334 343/13 45 CIN 1 NA 
100 23009 346/13 55 LCNKSCC GRADE 2 
101 41231 348/13 30 CIN 1 NA 
102 48011 357/13 37 CIN 3 NA 
103 48059 358/13 27 CIN 1 NA 
104 48101 364/13 26 CIN 1 NA 
105 48056 369/13 48 LCKSCC GRADE 1 
106 251626 374/13 32 LCNKSCC GRADE 2 
107 481044 380/13 50 LCNKSCC GRADE 2 
108 481019 381/13 25 CIN 1 NA 
109 28532 387/13 55 CIN 1 NA 
110 28891 396/13 47 LCKSCC GRADE 1 
111 48181 397/13 40 LCNKSCC GRADE 2 
112 48058 403/13 45 CIN 1 NA 
113 252133 407/13 65 LCNKSCC GRADE 2 
114 44550 410/13 71 CIN 1 NA 
115 48236 412/13 36 CIN 1 NA 
116 44823 431/13 40 CIN 1 NA 
117 21250 436/13 49 CIN 1 NA 
118 44798 439/13 47 LCNKSCC GRADE 2 
119 44661 445/13 70 CIN 1 NA 
120 44673 447/13 37 LCNKSCC GRADE 2 
121 44601 452/13 45 LCNKSCC GRADE 2 
122 252805 455/13 48 CIN 2 NA 
123 252179 457/13 60 LCNKSCC GRADE 2 
124 54310 461/13 32 CIN 3 NA 
125 44862 473/13 45 CIN 2 NA 
126 44954 483/13 62 CLEARCELL AC 
127 54423 488/13 35 LCNKSCC GRADE 2 
128 54371 489/13 50 ADENO SCC 
129 54431 491/13 45 LCKSCC GRADE 1 
130 54458 494/13 30 CIN 1 NA 
131 41286 496/13 45 CIN 1 NA 
132 61551 499/13 65 LCNKSCC GRADE 2 
133 61519 502/13 60 CIN 1 NA 
134 59200 508/13 27 CIN 1 NA 
135 59056 513/13 50 LCKSCC GRADE 1 
136 61763 524/13 50 LCKSCC GRADE 1 
137 61770 526/13 35 CIN 1 NA 
138 2065 535/13 40 SCC WITH MICROINVASION 
139 61822 539/13 32 CIN 1 NA 
140 61940 540/13 65 LCNKSCC GRADE 2 
141 61894 541/13 38 CIN 1 NA 
142 41134 546/13 28 LCNKSCC GRADE 2 
143 41267 548/13 70 LCNKSCC GRADE 2 
144 62365 555/13 50 CIN 1 NA 
145 62337 556/13 39 CIN 1 NA 
146 62332 557/13 45 CIN 1 NA 
147 61597 562/13 35 CIN 1 NA 
148 61602 566/13 46 CIN 1 NA 
149 61600 567/13 27 CIN 2 NA 
150 54291 571/13 55 LCNKSCC GRADE 2 
151 254988 576/13 60 LCNKSCC GRADE 2 
152 68171 592/13 50 CIN 1 NA 
153 68441 594/13 62 LCNKSCC GRADE 2 
154 23087 601/13 60 CIN 1 NA 
155 68457 605/13 45 LCNKSCC GRADE 2 
156 41139 612/13 28 LCNKSCC GRADE 2 
157 164678 621/13 45 CIN 1 NA 
158 68715 622/13 44 CIN 1 NA 
159 68676 623/13 50 LCNKSCC GRADE 2 
160 68677 624/13 50 SCNKSCC GRADE 3 
161 68754 625/13 62 VILLOGLANDULAR AC 
162 68795 631/13 40 CIN 1 NA 
163 68962 640/13 48 CIN 1 NA 
164 68975 641/13 50 LCNKSCC GRADE 2 
165 68972 642/13 55 LCNKSCC GRADE 2 
166 73599 656/13 60 LCNKSCC GRADE 2 
167 79530 658/13 77 LCNKSCC GRADE 2 
168 79660 666/13 40 CIN 1 NA 
169 79650 667/13 55 LCNKSCC GRADE 2 
170 79680 682/13 60 LCNKSCC GRADE 2 
171 1129 691/13 37 CIN 2 NA 
172 81648 694/13 38 LCNKSCC GRADE 2 
173 81678 697/13 65 LCNKSCC GRADE 2 
174 1902803 701/13 50 LCNKSCC GRADE 2 
175 81586 706/13 37 CIN 1 NA 
176 79928 714/13 45 SCNKSCC GRADE 3 
177 79924 716/13 45 CIN 1 NA 
178 81828 723/13 27 CIN 1 NA 
179 68630 730/13 70 LCKSCC GRADE 1 
180 2541532 741/13 50 SCC WITH MICROINVASION 
181 81992 758/13 31 CIN 1 NA 
182 88079 765/13 30 CIN 1 NA 
183 68846 766/13 50 CIN 2 NA 
184 88527 769/13 30 CIN 1 NA 
185 88154 777/13 45 SQUAMOTRANSITIONAL SCC 
186 88257 778/13 70 LCNKSCC GRADE 2 
187 88258 779/13 32 CIN 1 NA 
188 81710 780/13 55 LCNKSCC GRADE 2 
189 88423 792/13 42 CIN 2 NA 
190 82532 800/13 31 CIN 1 NA 
191 82573 807/13 40 CIN 1 NA 
192 82829 810/13 37 CIN 1 NA 
193 32622 814/13 50 CIN 1 NA 
194 82562 815/13 41 LCNKSCC GRADE 2 
195 82865 828/13 36 CIN 1 NA 
196 82862 835/13 25 CIN 1 NA 
197 82836 837/13 40 LCKSCC GRADE 1 
198 83147 859/13 50 LCNKSCC GRADE 2 
199 83059 862/13 38 CIN 1 NA 
200 83051 864/13 60 LCNKSCC GRADE 2 
201 83028 865/13 60 LCNKSCC GRADE 2 
202 83106 876/13 60 LCNKSCC GRADE 2 
203 83252 885/13 65 LCNKSCC GRADE 2 
204 83445 891/13 35 LCNKSCC GRADE 2 
205 259784 893/13 50 LCNKSCC GRADE 2 
206 87733 897/13 60 LCKSCC GRADE 1 
207 87539 899/13 57 LCKSCC GRADE 1 
208 88323 908/13 39 CIN 1 NA 
209 87533 913/13 42 LCKSCC GRADE 1 
210 87731 918/13 40 CIN 1 NA 
211 4480 919/13 45 CIN 3 NA 
212 87738 924/13 37 CIN 1 NA 
213 78555 930/13 26 LCKSCC GRADE 1 
214 87862 931/13 50 LCNKSCC GRADE 2 
215 87653 938/13 40 CIN 1 NA 
216 89082 943/13 60 CIN 3 NA 
217 260402 956/13 50 LCKSCC GRADE 1 
218 83017 958/13 35 LCNKSCC GRADE 2 
219 87959 964/13 65 LCNKSCC GRADE 2 
220 89198 965/13 60 LCNKSCC GRADE 2 
221 89328 970/13 45 CIN 3 NA 
222 87622 975/13 52 CIN 1 NA 
223 87673 976/13 50 LCNKSCC GRADE 2 
224 89203 978/13 50 LCNKSCC GRADE 2 
225 88086 985/13 45 CIN 1 NA 
226 88151 987/13 32 CIN 1 NA 
227 88247 1002/13 55 LCNKSCC GRADE 2 
228 83248 1005/13 50 LCNKSCC GRADE 2 
229 89026 1007/13 60 LCKSCC GRADE 1 
230 88461 1013/13 45 LCNKSCC GRADE 2 
231 88493 1016/13 60 CIN 2 NA 
232 99535 1025/13 30 CIN 1 NA 
233 259833 1028/13 49 LCNKSCC GRADE 2 
234 89392 1029/13 40 CIN 1 NA 
235 41358 1031/13 32 CIN 1 NA 
236 99787 1038/13 40 LCNKSCC GRADE 2 
237 99570 1044/13 60 LCNKSCC GRADE 2 
238 99672 1045/13 60 LCNKSCC GRADE 2 
239 88177 1050/13 40 CIN 1 NA 
240 99613 1052/13 40 CIN 3 NA 
241 99624 1055/13 33 SCC WITH MICROINVASION 
242 88213 1059/13 46 CIN 2 NA 
243 99892 1064/13 49 SCC WITH MICROINVASION 
244 99981 1065/13 42 LCNKSCC GRADE 2 
245 68643 1075/13 45 LCNKSCC GRADE 2 
246 99710 1076/13 40 CIN 1 NA 
247 76123 1080/13 50 LCNKSCC GRADE 2 
248 99013 1085/13 50 LCNKSCC GRADE 2 
249 87739 1102/13 46 LCNKSCC GRADE 2 
250 82023 1105/13 50 LCNKSCC GRADE 2 
251 200836 1109/13 30 CIN 1 NA 
252 280617 1111/13 32 CIN 1 NA 
253 89666 1128/13 60 CIN 1 NA 
254 1196 1170/13 60 LCNKSCC GRADE 2 
255 1207 1171/13 65 LCNKSCC GRADE 2 
256 1255 1172/13 60 LCNKSCC GRADE 2 
257 1234 1179/13 35 LCNKSCC GRADE 2 
258 264835 1180/13 60 LCNKSCC GRADE 2 
259 264855 1181/13 55 LCKSCC GRADE 1 
260 264321 1187/13 50 LCNKSCC GRADE 2 
261 17911 1188/13 40 CIN 1 NA 
262 1916 1191/13 40 LCNKSCC GRADE 2 
263 1948 1196/13 60 LCKSCC GRADE 1 
264 1247 1201/13 32 CIN 1 NA 
265 1119 1210/13 50 LCNKSCC GRADE 2 
266 6595 1219/13 35 CIN 1 NA 
267 6685 1234/13 37 CIN 1 NA 
268 6584 1239/13 50 LCNKSCC GRADE 2 
269 6772 1245/13 35 LCNKSCC GRADE 2 
270 6853 1255/13 48 LCNKSCC GRADE 2 
271 6838 1258/13 39 CIN 1 NA 
272 78965 1268/13 45 LCKSCC GRADE 1 
273 6867 1269/13 45 CIN 1 NA 
274 6993 1274/13 29 LCNKSCC GRADE 2 
275 6785 1282/13 37 CIN 3 NA 
276 6987 1283/13 50 CIN 3 NA 
277 17109 1295/13 40 LCNKSCC GRADE 2 
278 17226 1302/13 60 LCNKSCC GRADE 2 
279 17298 1304/13 48 LCNKSCC GRADE 2 
280 17365 1309/13 35 CIN 1 NA 
281 17646 1310/13 40 LCNKSCC GRADE 2 
282 6636 1321/13 60 CIN 3 NA 
283 17646 1337/13 34 CIN 1 NA 
284 17385 1341/13 32 CIN 2 NA 
285 17600 1352/13 60 LCNKSCC GRADE 2 
286 17765 1363/13 50 LCNKSCC GRADE 2 
287 17762 1364/13 65 LCKSCC GRADE 1 
288 17910 1371/13 70 LCNKSCC GRADE 2 
289 17915 1373/13 30 CIN 1 NA 
290 17865 1381/13 60 LCNKSCC GRADE 2 
291 20758 1396/13 39 LCNKSCC GRADE 2 
292 20700 1401/13 40 LCNKSCC GRADE 2 
293 20650 1402/13 85 LCNKSCC GRADE 2 
294 264797 1405/13 40 LCKSCC GRADE 1 
295 24567 1418/13 55 LCNKSCC GRADE 2 
296 24546 1432/13 50 LCNKSCC GRADE 2 
297 267427 1438/13 34 LCNKSCC GRADE 2 
298 24717 1457/13 65 LCNKSCC GRADE 2 
299 24847 1464/13 42 LCNKSCC GRADE 2 
300 24956 1471/13 47 CIN 1 NA 
301 31383 1489/13 39 CIN 2 NA 
302 21379 1496/13 55 LCNKSCC GRADE 2 
303 128274 1498/13 35 CIN 1 NA 
304 126753 1501/13 52 CIN 3 NA 
305 31598 1504/13 33 SCC WITH MICROINVASION 
306 31632 1506/13 30 CIN 3 NA 
307 31520 1515/13 31 CIN 1 NA 
308 31555 1521/13 35 CIN 1 NA 
309 31660 1527/13 39 CIN 3 NA 
310 31784 1545/13 48 CIN 1 NA 
311 31757 1546/13 31 CIN 1 NA 
312 24014 1548/13 40 LCNKSCC GRADE 2 
313 24242 1559/13 40 LCNKSCC GRADE 2 
314 24111 1562/13 55 LCNKSCC GRADE 2 
315 24098 1563/13 72 LCNKSCC GRADE 2 
316 24234 1577/13 51 CIN 2 NA 
317 24222 1579/13 70 LCNKSCC GRADE 2 
318 24382 1593/13 40 CIN 1 NA 
319 24455 1605/13 30 CIN 1 NA 
320 6902 1612/13 50 LCNKSCC GRADE 2 
321 34588 1613/13 50 LCNKSCC GRADE 2 
322 34754 1622/13 36 CIN 1 NA 
323 24436 1630/13 55 LCNKSCC GRADE 2 
324 24391 1637/13 60 LCKSCC GRADE 1 
325 1407 1639/13 50 CIN 3 NA 
326 34890 1648/13 65 LCNKSCC GRADE 2 
327 34857 1654/13 39 CIN 1 NA 
328 34832 1658/13 30 CIN 1 NA 
329 34198 1689/13 36 CIN 1 NA 
330 34060 1694/13 45 LCNKSCC GRADE 2 
331 34057 1700/13 45 CIN 3 NA 
332 34166 1715/13 45 CIN 3 NA 
333 34388 1721/13 46 LCNKSCC GRADE 2 
334 34406 1723/13 43 LCKSCC GRADE 1 
335 34446 1724/13 30 CIN 1 NA 
336 269863 1725/13 43 ENDOCERVICAL AC GRADE 2 
337 34103 1732/13 50 LCNKSCC GRADE 2 
338 38595 1735/13 39 CIN 2 NA 
339 265273 1740/13 53 CIN 1 NA 
340 268032 1741/13 40 CIN 1 NA 
341 34222 1755/13 70 LCNKSCC GRADE 2 
342 38980 1759/13 55 LCNKSCC GRADE 2 
343 38934 1763/13 67 LCNKSCC GRADE 2 
344 38891 1765/13 55 LCNKSCC GRADE 2 
345 38993 1775/13 34 CIN 2 NA 
346 43641 1776/13 55 LCNKSCC GRADE 2 
347 43633 1785/13 47 LCNKSCC GRADE 2 
348 38860 1789/13 32 CIN 2 NA 
349 43830 1793/13 65 LCNKSCC GRADE 2 
350 43972 1810/13 30 LCNKSCC GRADE 2 
351 126295 1813/13 35 LCNKSCC GRADE 2 
352 44330 1821/13 35 CIN 2 NA 
353 44243 1822/13 90 LCNKSCC GRADE 2 
354 1905756 1832/13 27 CIN 3 NA 
355 44211 1838/13 55 LCNKSCC GRADE 2 
356 44173 1843/13 37 CIN 2 NA 
357 44289 1847/13 31 CIN 3 NA 
358 44493 1856/13 50 CIN 2 NA  
359 44521 1858/13 35 CIN 1 NA 
360 38656 1861/13 35 LCNKSCC GRADE 2 
361 1881 1872/13 47 LCNKSCC GRADE 2 
362 44887 1875/13 45 LCNKSCC GRADE 2 
363 44547 1876/13 56 LCNKSCC GRADE 2 
364 44659 1897/13 45 LCNKSCC GRADE 2 
365 44580 1899/13 40 CIN 1 NA 
366 51002 1903/13 70 LCNKSCC GRADE 2 
367 44601 1907/13 55 LCNKSCC GRADE 2 
368 44754 1910/13 70 LCKSCC GRADE 1 
369 56074 1916/13 37 LCNKSCC GRADE 2 
370 50080 1920/13 34 CIN 1 NA 
371 51004 1921/13 65 LCNKSCC GRADE 2 
372 50312 1928/13 44 SCNKSCC GRADE 3 
373 273730 1930/13 50 LCKSCC GRADE 1 
374 50215 1934/13 70 SCNKSCC GRADE 3 
375 50338 1936/13 55 LCNKSCC GRADE 2 
376 44617 1943/13 66 LCNKSCC GRADE 2 
377 34055 1958/13 30 CIN 1 NA 
378 51148 1961/13 55 LCNKSCC GRADE 2 
379 50561 1978/13 60 LCNKSCC GRADE 2 
380 50749 2011/13 35 CIN 1 NA 
381 50987 2020/13 50 LCNKSCC GRADE 2 
382 50968 2023/13 60 LCNKSCC GRADE 2 
383 50966 2041/13 60 LCKSCC GRADE 1 
384 53646 2043/13 35 LCNKSCC GRADE 2 
385 53573 2045/13 40 LCNKSCC GRADE 2 
386 53809 2060/13 50 LCNKSCC GRADE 2 
387 53026 2067/13 50 LCNKSCC GRADE 2 
388 1473659 2070/13 50 LCKSCC GRADE 1 
389 1234 2074/13 40 CIN 1 NA 
390 53897 2076/13 65 LCNKSCC GRADE 2 
391 53830 2083/13 60 LCNKSCC GRADE 2 
392 53786 2086/13 30 CIN 1 NA 
393 80455 2090/13 75 LCNKSCC GRADE 2 
394 136459 2097/13 40 SCNKSCC GRADE 3 
395 27228 2103/13 37 LCNKSCC GRADE 2 
396 53219 2108/13 43 LCNKSCC GRADE 2 
397 53171 2111/13 35 CIN 1 NA 
398 50766 2113/13 60 LCNKSCC GRADE 2 
399 274097 2114/13 27 ADENOID SCC 
400 287288 2122/13 37 CIN 1 NA 
401 53309 2126/13 65 LCKSCC GRADE 1 
402 53318 2129/13 30 CIN 1 NA 
403 53322 2132/13 39 CIN 1 NA 
404 53342 2135/13 45 CIN 1 NA 
405 53292 2137/13 46 LCNKSCC GRADE 2 
406 56199 2151/13 38 CIN 3 NA 
407 53416 2155/13 55 LCKSCC GRADE 1 
408 56409 2176/13 54 CIN 1 NA 
409 56160 2189/13 45 CIN 1 NA 
410 1474657 2194/13 50 LCNKSCC GRADE 2 
411 56007 2204/13 60 LCNKSCC GRADE 2 
412 56077 2211/13 53 CIN 1 NA 
413 1906965 2216/13 60 SCC WITH MICROINVASION 
414 56161 2217/13 50 LCKSCC GRADE 1 
415 56211 2218/13 40 CIN 1 NA 
416 56057 2220/13 24 CIN 1 NA 
417 56147 2228/13 43 CIN 1 NA 
418 56342 2233/13 45 SCC WITH MICROINVASION 
419 56147 2247/13 55 LCNKSCC GRADE 2 
420 277347 2254/13 55 SCNKSCC GRADE 3 
421 56449 2261/13 70 CIN 2 NA  
422 56781 2275/13 37 CIN 1 NA 
423 56757 2277/13 37 SCC WITH MICROINVASION 
424 56707 2281/13 65 LCNKSCC GRADE 2 
425 274398 2282/13 66 LCNKSCC GRADE 2 
426 56689 2283/13 45 LCKSCC GRADE 1 
427 56670 2284/13 60 SCC WITH MICROINVASION 
428 56649 2286/13 50 LCKSCC GRADE 1 
429 56625 2294/13 40 CIN 1 NA 
430 110597 2301/13 32 CIN 1 NA 
431 53487 2310/13 35 CIN 1 NA 
432 531167 2311/13 50 LCNKSCC GRADE 2 
433 53118 2314/13 50 SCC WITH MICROINVASION 
434 56951 2315/13 30 CIN 1 NA 
435 160864 2320/13 48 CIN 1 NA  
436 57893 2322/13 38 CIN 1 NA 
437 60554 2324/13 40 CIN 1 NA 
438 60786 2345/13 52 CIN 1 NA  
439 60817 2347/13 37 CIN 2 NA 
440 60711 2353/13 35 LCNKSCC GRADE 2 
441 622183 2367/13 34 CIN 1 NA 
442 62141 2369/13 35 CIN 1 NA 
443 62274 2371/13 40 LCNKSCC GRADE 2 
444 62034 2372/13 43 CIN 1 NA 
445 62027 2376/13 45 LCNKSCC GRADE 2 
446 62013 2379/13 45 CIN 1 NA 
447 60861 2382/13 43 SCC WITH MICROINVASION 
448 60723 2383/13 29 CIN 1 NA 
449 277539 2385/13 40 LCNKSCC GRADE 2 
450 62375 2396/13 37 LCNKSCC GRADE 2 
451 62401 2408/13 37 CIN 2 NA 
452 111061 2416/13 30 CIN 1 NA 
453 62114 2422/13 52 LCNKSCC GRADE 2 
454 65387 2429/13 75 ENDOCERVICAL AC GRADE 3 
455 65382 2432/13 65 LCKSCC GRADE 1 
456 62467 2434/13 55 LCNKSCC GRADE 2 
457 62111 2438/13 70 LCNKSCC GRADE 2 
458 65295 2443/13 60 LCNKSCC GRADE 2 
459 65307 2444/13 60 LCKSCC GRADE 1 
460 65503 2462/13 70 LCKSCC GRADE 1 
461 23037 2475/13 60 CIN 1 NA 
462 65576 2476/13 60 LCKSCC GRADE 1 
463 65065 2492/13 51 LCNKSCC GRADE 2 
464 65527 2496/13 55 CGIN NA 
465 62485 2502/13 47 LCNKSCC GRADE 2 
466 241812 2506/13 57 LCNKSCC GRADE 2 
467 65590 2513/13 47 LCNKSCC GRADE 2 
468 65619 2515/13 45 CIN 1 NA 
469 65752 2528/13 40 CIN 1 NA 
470 54123 2537/13 46 LCNKSCC GRADE 2 
471 65853 2539/13 45 LCNKSCC GRADE 2 
472 65897 2543/13 40 CIN 2 NA 
473 250580 2544/13 50 ENDOMETRIOID AC 
474 65976 2557/13 21 CIN 1 NA 
475 65800 2572/13 55 CIN 2 NA 
476 65682 2577/13 38 LCNKSCC GRADE 2 
477 65764 2581/13 70 LCNKSCC GRADE 2 
478 65809 2582/13 60 CIN 2 NA 
479 65825 2585/13 40 LCKSCC GRADE 1 
480 65936 2603/13 58 LCNKSCC GRADE 2 
481 275949 2617/13 67 LCNKSCC GRADE 2 
482 258544 2628/13 45 LCNKSCC GRADE 2 
483 68472 2638/13 35 CIN 1 NA 
484 68476 2641/13 50 CIN 1 NA 
485 281198 2651/13 59 LCNKSCC GRADE 2 
486 68575 2656/13 39 CIN 1 NA 
487 56401 2662/13 30 CIN 1 NA 
488 68250 2663/13 35 CIN 1 NA 
489 279839 2667/13 40 ENDOCERVICAL AC GRADE 1 
490 281821 2668/13 45 LCNKSCC GRADE 2 
491 74536 2670/13 62 LCNKSCC GRADE 2 
492 68879 2676/13 49 LCNKSCC GRADE 2 
493 68781 2681/13 55 LCKSCC GRADE 1 
494 68855 2684/13 40 PAPILLARY SCC 
495 28005 2687/13 44 ENDOCERVICAL AC GRADE 3 
496 283235 2697/13 57 ENDOCERVICAL AC GRADE 2 
497 74580 2698/13 60 CIN 1 NA 
498 74619 2701/13 34 CIN 1 NA 
499 68642 2703/13 50 CIN 1 NA 
500 68693 2716/13 40 CIN 1 NA 
501 65094 2717/13 50 CIN 1 NA 
502 60861 2720/13 55 LCNKSCC GRADE 2 
503 74693 2721/13 55 LCNKSCC GRADE 2 
504 6867 2729/13 38 CIN 1 NA 
505 68422 2730/13 50 LCNKSCC GRADE 2 
506 68720 2732/13 37 CIN 1 NA 
507 74694 2734/13 45 PAPILLARY SCC 
508 74728 2735/13 32 CIN 1 NA 
509 283926 2737/13 50 LCNKSCC GRADE 2 
510 65655 2739/13 48 LCNKSCC GRADE 2 
511 34366 2745/13 47 CIN 1 NA 
512 65595 2747/13 65 LCKSCC GRADE 1 
513 80785 2750/13 50 BASALOID SCC 
514 80784 2751/13 38 CIN 1 NA 
515 80778 2752/13 45 CIN 1 NA 
516 87854 2754/13 35 CIN 2 NA 
517 80700 2765/13 50 LCNKSCC GRADE 2 
518 80795 2766/13 36 CIN 1 NA 
519 74518 2767/13 30 CIN 1 NA 
520 80821 2772/13 38 LCNKSCC GRADE 2 
521 284131 2773/13 40 CIN 1 NA 
522 80912 2781/13 56 LCNKSCC GRADE 2 
523 87079 2798/13 35 CIN 1 NA 
524 156151 2804/13 67 CIN 1 NA 
525 155781 2805/13 50 LCNKSCC GRADE 2 
526 87474 2811/13 42 CIN 1 NA 
527 90006 2812/13 55 LCNKSCC GRADE 2 
528 87439 2816/13 70 LCNKSCC GRADE 2 
529 87401 2817/13 55 LCNKSCC GRADE 2 
530 87431 2828/13 80 LCNKSCC GRADE 2 
531 90098 2837/13 60 BASALOID SCC 
532 90102 2838/13 55 LCNKSCC GRADE 2 
533 90182 2848/13 43 LCNKSCC GRADE 2 
534 90129 2851/13 52 LCNKSCC GRADE 2 
535 27402 2854/13 53 CIN 1 NA 
536 90271 2855/13 50 LCNKSCC GRADE 2 
537 90876 2857/13 30 LCNKSCC GRADE 2 
538 31554 2859/13 60 LCNKSCC GRADE 2 
539 90373 2865/13 65 LCNKSCC GRADE 2 
540 90436 2868/13 80 LCNKSCC GRADE 2 
541 90387 2871/13 60 LCNKSCC GRADE 2 
542 90727 2884/13 50 LCNKSCC GRADE 2 
543 74688 2886/13 31 CIN 1 NA 
544 90807 2893/13 35 CIN 1 NA 
545 90819 2896/13 50 LCNKSCC GRADE 2 
546 90657 2903/13 45 CIN 1 NA 
547 90456 2904/13 55 LCKSCC GRADE 1 
548 90868 2907/13 30 CIN 1 NA 
549 90914 2908/13 60 LCNKSCC GRADE 2 
550 90873 2909/13 32 CIN 1 NA 
551 90871 2910/13 32 CIN 1 NA 
552 90976 2915/13 45 ENDOCERVICAL AC GRADE 2 
553 1488634 2922/13 38 CIN 1 NA 
554 100256 2923/13 46 CIN 1 NA 
555 100293 2925/13 40 CIN 1 NA 
556 90887 2927/13 41 CIN 1 NA 
557 100101 2930/13 45 CIN 1 NA 
558 100083 2931/13 41 CIN 2 NA 
559 90730 2936/13 52 CIN 2 NA 
560 100352 2937/13 45 CIN 1 NA 
561 100075 2945/13 41 CIN 1 NA 
562 113512 2947/13 48 CIN 1 NA 
563 121470 2955/13 36 CIN 1 NA 
564 87304 2961/13 48 CIN 3 NA 
565 91003 2962/13 60 LCNKSCC GRADE 2 
566 287602 2971/13 43 CIN 3 NA 
567 91101 2972/13 34 CIN 1 NA 
568 91187 2980/13 40 CIN 1 NA 
569 91267 2991/13 50 LCNKSCC GRADE 2 
570 286904 2992/13 55 LCNKSCC GRADE 2 
571 91325 2996/13 40 CIN 1 NA 
572 91337 2998/13 34 CIN 1 NA 
573 91297 3004/13 35 CIN 1 NA 
574 91391 3005/13 38 CIN 1 NA 
575 91345 3008/13 35 CIN 1 NA 
576 100230 3009/13 40 CIN 1 NA 
577 91287 3018/13 45 LCNKSCC GRADE 2 
578 91620 3024/13 50 LCNKSCC GRADE 2 
579 83770 3028/13 62 LCNKSCC GRADE 2 
580 91785 3039/13 37 CIN 1 NA 
581 91783 3043/13 40 CIN 1 NA 
582 91844 3046/13 27 CIN 1 NA 
583 91897 3049/13 31 CIN 1 NA 
584 91860 3052/13 65 LCNKSCC GRADE 2 
585 91949 3053/13 33 CIN 1 NA 
586 91935 3058/13 50 CIN 1 NA 
587 91972 3059/13 58 LCNKSCC GRADE 2 
588 100201 3066/13 35 CIN 1 NA 
589 691847 3073/13 39 CIN 1 NA 
590 1546 3084/13 40 CIN 3 NA 
591 105002 3093/13 46 CIN 1 NA 
592 287691 3100/13 45 SCC WITH MICROINVASION 
593 105024 3101/13 62 LCNKSCC GRADE 2 
594 105139 3108/13 30 CIN 1 NA 
595 105094 3118/13 50 CIN 2 NA 
596 105689 3124/13 68 LCKSCC GRADE 1 
597 105218 3125/13 30 CIN 1 NA 
598 105369 3146/13 27 CIN 1 NA 
599 105340 3149/13 60 CIN 1 NA 
600 105331 3152/13 34 CIN 1 NA 
601 112598 3159/13 60 LCNKSCC GRADE 2 
602 665 3160/13 48 CIN 2 NA 
603 112624 3161/13 31 CIN 1 NA 
604 112773 3167/13 21 CIN 1 NA 
605 289690 3168/13 44 LCNKSCC GRADE 2 
606 112802 3169/13 45 PAPILLARY SCC 
607 112728 3170/13 65 LCNKSCC GRADE 2 
608 112836 3174/13 31 CIN 1 NA 
 
 
 
 
 
 
IMMUNOHISTOCHEMICAL ANALYSIS OF p16
INK4a
 EXPRESSIONS IN CERVICAL LESIONS 
S.
N
O 
HP .NO AGE 
WHO 
CLASSIFIC
ATION 
TYPE OF 
STAINING 
PROPORTION 
OF POSITIVE 
TUMOR CELLS 
INTENSITY 
OF 
STAINING 
PATTERN 
OF STAINIG 
1 P910/13 30 CNSC NEGATIVE - - - 
2 P1528/13 39 CNSC NEGATIVE - - - 
3 P1596/13 34 CNSC NEGATIVE - - - 
4 P2055/13 30 CNSC NEGATIVE - - - 
5 P2061/13 40 CNSC CYTOPLASMIC 2 2 DIFFUSE BASAL 
6 P2123/13 26 CNSC NEGATIVE - - - 
7 P2133/13 27 CNSC N:C 1 1 PATCHY 
8 P2988/13 33 CNSC NEGATIVE - - - 
9 P3126/13 30 CNSC NEGATIVE - -           - 
10 P1234/13 37 CIN 1 N:C 2 1 DIFFUSE BASAL 
11 P1605/13 30 CIN 1 N:C 1 2 PATCHY 
12 P1689/13 36 CIN 1 N:C 2 2 DIFFUSE BASAL 
13 P1740/13 53 CIN 1 N:C 1 1 PATCHY 
14 P1858/13 35 CIN 1 N:C 1 1 DIFFUSE BASAL 
15 P2310/13 35 CIN 1 N:C 1 3 PATCHY 
16 P2656/13 39 CIN 1 N:C 1 2 DIFFUSE BASAL 
17 P2893/13 35 CIN 1 CYTOPLASMIC 2 2 DIFFUSE BASAL 
18 P3005/13 38 CIN 1 CYTOPLASMIC 1 1 PATCHY 
19 P3073/13 39 CIN 1 CYTOPLASMIC 2 2 DIFFUSE BASAL 
20 P1341/13 32 CIN 2 N:C 2 3 DIFFUSE BASAL 
21 P1489/13 39 CIN 2 N:C 1 1 PATCHY 
22 P1775/13 34 CIN 2 N:C 2 3 DIFFUSE BASAL 
23 P1789/13 32 CIN 2 N:C 2 2 DIFFUSE BASAL 
24 P1856/13 50 CIN 2 N:C 2 2 DIFFUSE BASAL 
25 P2261/13 70 CIN 2 N:C 2 2 DIFFUSE BASAL 
26 P2347/13 37 CIN 2 N:C 2 1 DIFFUSE BASAL 
27 P2408/13 37 CIN 2 N:C 2 3 DIFFUSE BASAL 
28 P2582/13 60 CIN 2 CYTOPLASMIC 1 1 DIFFUSE BASAL 
29 P3160/13 48 CIN 2 N:C 2 2 DIFFUSE BASAL 
30 P183/13 37 CIN3 N:C 3 3 DIFFUSE FULL THICK 
31 P970/13 45 CIN 3 N:C 2 2 DIFFUSE BASAL 
32 P1283/13 50 CIN 3 CYTOPLASMIC 2 1 DIFFUSE FULL THICK 
33 P1527/13 39 CIN 3 N:C 3 3 DIFFUSE FULL THICK 
34 P1700/13 45 CIN 3 N:C 2 2 DIFFUSE BASAL 
35 P1715/13 45 CIN 3 N:C 2 3 DIFFUSE FULL THICK 
36 P1832/13 27 CIN 3 N:C 3 3 DIFFUSE BASAL 
37 P1847/13 31 CIN 3 N:C 1 2 PATCHY 
38 P2151/13 38 CIN 3 N:C 3 3 DIFFUSE FULL THICK 
39 P2961/13 48 CIN 3 CYTOPLASMIC 2 1 DIFFUSE BASAL 
40 P1055/13 33 SCC WITH MI N:C 3 3 NA 
41 P2233/13 45 SCC WITH MI N:C 3 2 NA 
42 P2277/13 37 SCC WITH MI N:C 3 3 NA 
43 P3100/13 45 SCC WITH MI N:C 3 3 NA 
44 P913/13 42 LCKSCC N:C 3 3 NA 
45 P1181/13 55 LCKSCC CYTOPLASMIC 3 2 NA 
46 P546/13 28 LCNKSCC N:C 3 3         NA 
47 P899/13 57 LCNKSCC N:C 3 3 NA 
48 P958/13 35 LCNKSCC CYTOPLASMIC 2 2 NA 
49 P1005/13 50 LCNKSCC N:C 3 3 NA 
50 P1180/13 60 LCNKSCC N:C 3 3 NA 
51 P1295/13 40 LCNKSCC N:C 3 3 NA 
52 P1310/13 40 LCNKSCC N:C 3 3 NA 
53 P1765/13 55 LCNKSCC CYTOPLASMIC 3 3 NA 
54 P1943/13 66 LCNKSCC N:C 3 3 NA 
55 P2812/13 55 LCNKSCC N:C 3 3 NA 
56 P3018/13 45 LCNKSCC N:C 3 3 NA 
57 P1928/13 44 SCNKSCC N:C 3 2 NA 
58 P1934/13 70 SCNKSCC CYTOPLASMIC 3 2 NA 
59 P162/13 43 ADENOSCC N:C 3 3 NA 
60 P2750/13 50 BASALOID SCC N:C 3 3 NA 
61 P3169/13 45 PAPILLARY SCC N:C 3 3 NA 
62 P777/13 45 ST SCC NUCLEAR 2 2 NA 
63 P2429/13 75 ENDO AC N:C 3 3 NA 
64 P483/13 62 CLEAR CELL AC N:C 3 3 NA 
65 P2544/13 50 ENDOMETRIOID AC N:C 3 3 NA 
66 P625/13 62 VILLOGLANDULAR AC CYTOPLASMIC 3 3 NA 
67 P2687/13 44 ENDO AC N:C 3 3 NA 
68 P2915/13 45 ENDO AC N:C 3 3 NA 
69 P2496/13 55 CGIN N:C 3 3 NA 
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                                     OBSERVATION AND RESULTS 
The present study was carried out to assess the prevalence of uterine cervical 
neoplasms in patients diagnosed at TMCH during the one year period from January 
2013 to December 2013.  
In one year study period, a total of 3198 cervical biopsies were received. In 
which 656 cases were diagnosed as uterine cervical neoplasms. All 656 cases were 
stained with Haematoxylin and eosin and reviewed; interobserver variations in 
diagnosing the cervical intraepithelial neoplasms were noted. Histologic findings like 
basal cell hyperplasia, reactive atypia were downgraded; cases reported as HSIL were 
categorized as CIN2 and CIN3 separately during review. After review, 608 cases were 
diagnosed as cervical neoplasms which constitute our study sample. 
5.1 INCIDENCE 
Among 3198 cervical biopsies received during the one year study period, 608 
cases of uterine cervical neoplasms were reported, which constitutes 19% of the total 
cervical biopsies. 
 The incidence of uterine cervical carcinoma is 10.38% and that of cervical 
intraepithelial neoplasia is 8.6%. 
The proportion of uterine cervical carcinoma (332 cases-54.61%) and cervical 
intraepithelial neoplasms (276 cases-45.39%) are in the ratio of 1.22:1. (table no-4, 
graph no-1) 
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TABLE NO-4 
INCIDENCE OF UTERINE CERVICAL NEOPLASMS 
HISTOPATHOLOGICAL 
DIAGNOSIS NO. OF CASES PERCENTAGE 
CIN 276 45.39 
CARCINOMA 332 54.61 
TOTAL 608 100 
 
GRAPH NO- 1 
 
5.2 HISTOPATHOLOGICAL EXAMINATION AND CLASSIFICATION 
The tumours were typed according to the WHO classification system 
(ANNEXURE IV).  
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5.2.a CERVICAL INTRAEPITHELIAL NEOPLASIA 
Cervical intraepithelial neoplasia were graded as CIN 1,2 and 3 based on the 
thickness of the epithelium showing loss of differentiation/ orderly maturation (basal 
1/3, 1/3 to 2/3 and >2/3),distribution of mitotic figures in the epithelium with presence 
of koilocytic atypia in CIN 1. The histopathological pictures of CIN 1, CIN 2, CIN 3 
and CGIN are depicted in figures: 5, 7, 9, 11 respectively. 
Among 276 cases, 210 cases (76%), 38 cases (14%), 27 cases (10%) and one 
case (0.37%) were classified as CIN1, CIN2, CIN3 and CGIN respectively. (Table 
no-5, graph no-2) 
TABLE NO-5 
DISTRIBUTION OF DIFFERENT TYPES OF CERVICAL 
INTRAEPITHELIAL NEOPLASMS 
HISTOPATHOLOGICAL 
DIAGNOSIS NO. OF CASES PERCENTAGE 
CIN 1 210 76 
CIN 2 38 14 
CIN 3 27 9.6 
CGIN 1 0.4 
TOTAL 276 100 
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GRAPH NO-2 
 
 
5.1.b MALIGNANT LESION OF CERVIX 
After analysing the data 332(55.44%) cases of cervical carcinoma were 
identified.  
Out of 332 cases, 318(95.79%) cases were Squamous cell carcinoma, 9(2.7%) 
cases were Adenocarcinoma and other epithelial tumours constitutes 4(1.2%) cases of 
AdenoSCC and one (0.3%) case of Adenoid Basal carcinoma. (table no-6, graph no- 3) 
The most of the malignant lesions occurred in the 5th and 6th decades. Mean 
age of malignant cases was 52.6 years. 
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TABLE NO - 6 
DISTRIBUTION OF DIFFERENT TYPES OF CERVICAL CARCINOMA 
HISTOPATHOLOGICAL DIAGNOSIS NO. OF CASES PERCENTAGE 
SQUAMOUS CELL CARCINOMA 318 95.8 
ADENOCARCINOMA 9 2.7 
OTHER EPITHELIAL TUMORS 5 1.5 
TOTAL 332 100 
 
GRAPH NO - 3 
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5.1.c SQUAMOUS CELL CARCINOMA OF THE UTERINE CERVIX: 
In this present study, SCC constitutes the majority of malignant lesions. Out of 
318 cases, 13 cases were SCC with microinvasion and 298 cases were conventional 
SCC. In conventional SCC, 49(15.41%) cases were Large cell Keratinizing SCC, 
238(74.84%) cases were Large cell Nonkeratinizing SCC, 11(3.46%) cases were Small 
cell Nonkeratinizing SCC. The histopathological pictures of squamous cell carcinoma 
with microinvasion and variants of SCC are depicted in figures: 13, 21, 23, 25, 39.  
Distribution of the histopathological variants of SCC encountered in our study are 
given in (table no-7, graph no -4) 
TABLE NO - 7 
DISTRIBUTION OF DIFFERENT TYPES OF SQUAMOUS CELL 
CARCINOMA 
HISTOPATHOLOGICAL DIAGNOSIS NO. OF CASES PERCENTAGE 
SCC WITH MICROINVASION 13 4 
LCKSCC 49 15.4 
LCNKSCC 238 74.8 
SCNKSCC 11 3.5 
PAPILLARY SCC 3 0.9 
BASALOID SCC 2 0.6 
SQUAMOTRANSITIONAL SCC 1 0.3 
ADENOID SCC 1 0.3 
TOTAL 318 100 
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GRAPH NO - 4 
 
 
5.1.d GRADING OF CONVENTIONAL SCC: 
In this study, all the conventional SCC were graded based on modified Broder’s 
method into three grades namely well, moderately and poorly differentiated 
carcinomas. As Keratinizing SCC (16.44%) was graded as Grade1, Large cell 
Nonkeratinizing SCC (79.86%) as Grade 2 and Small cell Nonkeratinizing (3.6%) as 
Grade 3. The histopathological pictures of LCKSCC, LCNKSCC and SCNKSCC are 
depicted in figures: 15, 17, 19. The distribution of different grades of conventional SCC 
is given in table no - 8 
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TABLE NO - 8 
DISTRIBUTION OF GRADE OF DIFFERENTIATION OF CONVENTIONAL 
SCC 
HISTOPATHOLOGICAL 
DIAGNOSIS 
GRADE OF 
DIFFERENTIATION 
NO. OF 
CASES PERCENTAGE 
LCKSCC 1 49 16.44 
LCNKSCC 2 238 79.86 
SCNKSCC 3 11 3.6 
TOTAL  298 100 
 
5.1.e ADENOCARCINOMA 
In this present study out of 9 cases of adenocarcinoma, 6 (66.7%) cases 
were of Mucinous adenocarcinoma of endocervical type were and the other three cases 
include Villoglandular adenocarcinoma, clear cell adenocarcinoma and 
Endometrioid adenocarcinoma (table no-9, graph no-5). The histopathological 
pictures of different types of adenocarcinoma are depicted in figures: 27, 29, 31, 33, 35.  
TABLE NO - 9 
DISTRIBUTION OF DIFFERENT TYPES OF ADENOCARCINOMA 
HISTOPATHOLOGICAL DIAGNOSIS NO. OF CASES PERCENTAGE 
VILLOGLANDULAR 1 11.1 
ENDOCERVICAL TYPE 6 66.7 
CLEAR CELL TYPE 1 11.1 
ENDOMETRIOID TYPE 1 11.1 
Total 9 100 
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GRAPH NO - 5 
 
 
5.1.f GRADING OF ADENOCARCINOMA 
In this study, Mucinous adenocarcinoma of endocervical type was graded, 
based on the complex architecture and the nuclear features into three grade i.e. well, 
moderately and poorly differentiated carcinoma as Grade 1, Grade 2 and Grade 3 
respectively. 
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Out of 6 cases of Mucinous adenocarcinoma of endocervical type, one case 
(16.66%) of Grade 1, three cases (50%) of Grade 2 and two cases (33.3%) of Grade 
3.(table no-10) were observed. The histopathological pictures of grade 2 and grade 3 
are depicted in figures: 31, 33. 
TABLE NO - 10 
DISTRIBUTION OF GRADE OF DIFFERENTIATION OF ENDOCERVICAL 
ADENOCARCINOMA 
GRADE OF DIFFERENTIATION NO. OF CASES PERCENTAGE 
Grade 1 1 16.7 
Grade 2 3 50 
Grade 3 2 33.3 
Total 6 100 
 
5.1.g OTHER EPITHELIAL TUMOURS 
In this present study, apart from SCC and adenocarcinoma, 4 cases of Adeno 
SCC and one case of Adenoid basal carcinoma were noted. The histopathological 
pictures of these tumours are depicted in figure: 37, 40. 
5.2 DISTRIBUTION OF CERVICAL NEOPLASMS ACCORDING TO AGE  
 The present study statistical study data inferred that majority of the uterine 
cervical neoplasms belonged to 30-60 years age group (510 cases-75.45%). 
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Among individual age groups most of the patients were in the 40-49 age group 
(166 cases-27.3%), followed by those belonging to 30-39 years age group (155 cases-
25.49%).  
In this present study, the age ranges from 21-90 years, with mean age of 46.8 
years. In one end of the spectrum, two cases were reported as CIN 1 at the age of 21 
years and in another end of the spectrum, a case has been reported as carcinoma at the 
age of 90 years.  
The peak incidence of cervical intraepithelial neoplasms of cervix was seen in 
the fourth decade which was two decades earlier than that observed in the carcinoma 
group of patients seen in the following graph no-6 
GRAPH NO – 6 
AGE-GROUP WISE INCIDENCE 
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The age wise distribution pattern of CIN and CARCINOMA are given in table no – 11 
and graph no – 7. 
TABLE NO - 11 
AGE GROUP WISE DISTRIBUTION PATTERN OF CIN AND CARCINOMA 
AGE GROUP(YEARS) 
NO. OF CIN 
CASES 
n (%) 
NO. OF 
CARCINOMA 
CASES n (%) 
TOTAL 
CASES 
n (%) 
20-29 21 (7.6%) 5 (1.5%) 26 (4.27%) 
30-39 127 (46%) 28 (8.43%) 155 (25.49%) 
40-49 82 (29.7%) 84 (25.3%) 166 (27.3%) 
50-59 31 (11.2%) 107 (32.22%) 138 (22.69%) 
60-69 12 (4.3%) 81 (24.39%) 93 (15.29%) 
70-79 3 (1%) 23 (6.9%) 26 (4.27%) 
80-89 0 00 3 (0.9%) 3 (0.49%) 
90-99 0 00 1 (0.3%) 1 (0.16%) 
TOTAL 276 100 332 100 608 100 
 
 
72 
 
GRAPH NO – 7 
AGE GROUP WISE DISTRIBUTION PATTERN OF CIN AND CARCINOMA 
 
5.2.b CERVICAL INTRAEPITHELIAL NEOPLASMS 
In the present study, the age group of two hundred and seventy six patients of 
cervical intraepithelial neoplasms of cervix aged from 21 to 71 years with a mean age 
of 39.8years.(table no-12, graph no-8) 
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TABLE NO - 12 
AGE GROUP WISE DISTRIBUTION PATTERN OF CERVICAL 
INTRAEPITHELIAL NEOPLASMS 
Age group(years) CIN 1 CIN 2 CIN 3 CGIN Total Percentage 
20-29 17 2 2 0 21 7.6 
30-39 104 14 9 0 127 46 
40-49 61 11 10 0 82 29.7 
50-59 19 7 4 1 31 11.2 
60-69 7 3 2 0 12 4.3 
70-79 2 1 0 0 3 1 
Total 210 38 27 1 276 100 
 
GRAPH NO – 8 
AGE GROUP WISE DISTRIBUTION PATTERN OF CERVICAL 
INTRAEPITHELIAL NEOPLASMS 
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CIN 1 
The majority of CIN 1 cases were found between 30-39 years (49.5%), with 
the minimum and maximum age being 21 years and 71 years respectively. The mean 
age for CIN 1 was 38.8 years  
CIN 2 
The maximum no. of CIN 2 cases were found between 30-39 years (36.84%), 
with the minimum and maximum age being 27 years and 70 years respectively. The 
mean age for CIN 2 was 43 years 
CIN 3 
The most cases of CIN 3 were found between 40-49 years (37%), with the 
minimum and maximum age being 27 years and 60 years respectively. The mean age 
for CIN 3 was 42 years. 
 CGIN 
In this present study, one case of CGIN was noted in a 55 years. 
5.2.c MALIGNANT LESIONS OF UTERINE CERVIX 
The age of the patients with carcinoma cervix ranged from 26 to 90 years with 
mean age of 52.6 years. The peak incidence of carcinoma of cervix was seen in the 
sixth decade.  
 
 
 
75 
 
5.2.d SQUAMOUS CELL CARCINOMA 
The maximum no. of SCC was found between 50-59 years age group 
(102 cases-31.9%), with the minimum and maximum age being 26 years and 90 years 
respectively. The mean age for SCC was 52.6 years. (table no-13, graph no-9) 
TABLE NO - 13 
AGEGROUP WISE DISTRIBUTION PATTERN OF SQUAMOUS CELL 
CARCINOMA 
Age 
group(years) 
SC
C 
MI 
LCKS
CC 
LCNKS
CC 
SCNKS
CC 
SCC 
Variants 
Total Percentage 
20-29 0 1 3 0 1 5 1.5 
30-39 3 1 24 0 0 28 8.8 
40-49 5 12 53 5 4 79 24.8 
50-59 2 16 81 2 1 102 32 
60-69 3 15 58 1 1 78 24.5 
70-79 0 4 15 3 0 22 6.9 
80-89 0 0 3 0 0 3 0.9 
90-99 0 0 1 0 0 1 0.3 
Total 13 49 238 11 7 318 100 
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GRAPH NO – 9 
AGE GROUP WISE DISTRIBUTION PATTERN OF SQUAMOUS CELL 
CARCINOMA 
 
SCC WITH MICROINVASION 
Majority of SCC with micro invasion was found between 40-49 years (38.46%), 
with the minimum and maximum age being 33 years and 67 years respectively. The 
mean age for SCC with microinvasion was 47 years. 
LARGE CELL KERATINIZING SQUAMOUS CELL CARCINOMA 
Most of LCKSCC cases were found between 50-59 years (32.65%), with the 
minimum and maximum age being 26 years and 70 years respectively. The mean age 
for LCKSCC was 53.9 years. 
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LARGE CELL NON KERATINIZING SQUAMOUS CELL CARCINOMA 
The most of LCNKSCC cases was found between 50-59 years (34%), with the 
minimum and maximum age being 28 years and 90 years respectively. The mean age 
for LCNKSCC was 52.7 years. 
SMALL CELL NON KERATINIZING SQUAMOUS CELL CARCINOMA 
Most of SCNKSCC cases were found between 40-49 years (45.45%), with the 
minimum and maximum age being 40 years and 73 years respectively. The mean age 
for SCNKSCC was 54.5 years. 
5.2.e HISTOLOGIC VARIANTS OF SCC 
Three cases of Papillary variant of SCC were noted in the fifth decade, two 
cases of Basaloid variant of SCC were seen in 50 and 60 years , one case of Adenoid 
SCC was seen in 27 years and a case of squamoustransistional variant was seen in 45 
years. 
 
5.2.f ADENOCARCINOMA 
The most of the Adenocarcinoma cases were found between 40-49 years 
(44.4%), with the minimum and maximum age being 40 years and 75 years 
respectively. The mean age for Adenocarcinoma was 53 years. (table no-14, graph-10) 
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TABLE NO - 14 
AGE GROUP WISE DISTRIBUTION PATTERN OF ADENOCARCINOMA 
Age group(years) No. of cases percentage 
20-29 0 00 
30-39 0 00 
40-49 4 44.4 
50-59 2 22.2 
60-69 2 22.2 
70-79 1 11.1 
Total 9 100 
 
GRAPH NO – 10 
AGE GROUP WISE DISTRIBUTION PATTERN OF 
ADENOCARCINOMA
 
5.2.g HISTOLOGIC VARIANTS OF ADENOCARCINOMA 
A case of Villoglandular adenocarcinoma and one case of Clear cell adenocarcinoma 
was seen in 62 years and a case of Endometroid adenocarcinoma was seen in 50 years. 
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TABLE NO - 15 
DISTRIBUTION OF CASES ACCORDING TO DIFFERENT 
HISTOPATHOLOGICAL DIAGNOSIS 
HISTOPATHOLOGICAL DIAGNOSIS 
FREQUE
NCY 
PERCENT
AGE 
CIN1 210 34.54 
CIN2 38 6.25 
CIN3 27 4.44 
CERVICAL 
INTRAEPITHELIAL 
NEOPLASMS 
CGIN 1 0.16 
SCC with microinvasion 13 2.14 
LCKSCC 49 8 
LCNKSCC 238 39.14 
CONVENTIO
NAL SCC 
SCNKSCC 11 1.8 
PAPILLARY SCC 3 0.49 
BASALOID SCC 2 0.32 
SQUAMOTRANSITIONAL 
SCC 
1 0.17 
SCC 
ADENOID SCC 1 0.17 
VILLOGLANDULAR AC 1 0.17 
ENDOCERVICAL TYPE 6 0.99 
CLEAR CELL AC 1 0.17 
ADENO 
CARCINOMA 
ENDOMETRIOID AC 1 0.16 
ADENO SCC 4 0.66 
CARCI
NOMA 
OTHER 
EPITHELIAL 
TUMOURS 
ADENOID BASAL 
CARCINOMA 
1 0.16 
TOTAL 608 100 
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GRAPH NO - 11 
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5.3 IMMUNOHISTOCHEMICAL ANALYSIS    
p16INK4a IMMUNOEXPRESSION IN CERVICAL NEOPLASMS 
Immunohistochemical staining using advanced polymer staining systems                 
(a mouse monoclonal anti-p16 antibody, Fremont, CA, 94538, Biogenex, USA) 
p16INK4a monoclonal antibody was used for 69 cases of uterine cervical biopsies 
according to the protocol (ANNEXURE III). 
The study group composed of randomly selected 69 cases, which represents 
10% of the sample size. Out of 69 cases, 9 cases of chronic non-specific cervicitis, 10 
cases of CIN 1, 10 cases of CIN 2, 10 cases of CIN 3, a case of CGIN, 22 cases of 
SCC, 6 cases of Adenocarcinoma and a case of Adenosquamous carcinoma were taken. 
 Squamous cell carcinoma cases includes 4 cases of SCC with microinvasion, 15 
cases of Conventional Squamous cell carcinoma and 3 cases of its variants which 
includes Papillary SCC, Basaloid SCC and Squamotransitional cell carcinoma.  
Among the conventional squamous cell carcinoma, 2 cases were Large cell 
keratinizing SCC, 11 Large cell non keratinizing SCC and 2 Small cell non keratinizing 
SCC which was graded into grade 1, grade 2 and grade 3 respectively, according to 
modified Broder’s classification.  
Adenocarcinoma and its variants taken for IHC includes, clear cell 
adenocarcinoma, Endometrioid adenocarcinoma, Villoglandular adenocarcinoma, 
endocervical mucinous adenocarcinoma of grade 2 and 2 cases of endocervical 
mucinous adenocarcinoma of grade 3. 
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5.3.a EVALUATION OF IMMUNOHISTOCHEMICAL MARKER-p16INK4a 
The immunostaining was considered positive when the nucleus and/or 
cytoplasm take chest nut brown colour. Various researchers have used different 
methods for scoring p16INK4a immunostaing, but in this study two different protocols 
were considered: 1) positive vs negative p16 immunostaining; 2) a semi-quantitative 
method based on four parameters for scoring which will eventually increase the 
specificity of the results and the parameters are as follows:  
1. Percentage of proportion of positive tumour cells42, 43,  44, 45, 46 were graded 
as: 
•  0% - negative staining - 0 
•  1-5% - 1+ 
•  5-25% - 2+  
• > 25% - 3+. 
2. Intensity of staining42, 44, 47, 48, 49-(0-3 points) 
• Negative - 0 
• Weak – 1+ 
• Moderate - 2+ 
• Strong - 3+ 
3. p16INK4a staining in cellular reaction pattern42, 44, 45, 49, 62- 
 Only cytoplasmic positivity 
 Nucleo: cytoplasmic positivity 
 Nuclear positivity  
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4. p16INK4a pattern staining expression in epithelium of different CIN grades 
42, 45, 50
 as stated in Lulin Hu publications,  
• Negative -- no positive cells or <1% positive cells.  
• Patchy -- focally aggregated positive cells contain <25% of epithelium.  
• Diffuse basal -- In lower half of broad area of epithelium if positive cells 
present in continuity.  
• Diffuse full thickness -- In lower half of broad area of epithelium if positive 
cells present in continuity with each other and in full thickness. 
 
5.3.b PROPORTION OF POSITIVE TUMOUR CELLS AMONG THE 
DIFFERENT GROUPS OF UTERINE CERVICAL LESIONS 
Based on the above parameters mentioned, 69 cases were studied and the results were 
shown in the following table no-16, graph-12, 13. 
TABLE NO - 16 
PROPORTION OF POSITIVE TUMOUR CELLS AMONG THE DIFFERENT GROUPS 
PROPORTION OF POSITIVE CELLS: n (%) CATEGORY NO.OF  
CASES 
(n) 0% (grade 0) 
1-5% 
(grade 1) 
5-25% 
(grade 2) 
>25% 
(grade 3) 
CNSC 9 7(77.7%) 1(11%) 1(11%) - 
CIN 1 10 - 6(60%) 4(40%) - 
CIN 2 10 - 2(20%) 8(80%) - 
CIN 3 10 - 1(10%) 5(50%) 4(40%) 
CIN 
CGIN 1 - - - 1(100%) 
SCC 22 - - 1(4.5%) 21(95.45%) 
AC 6 - - - 6(100%) 
CA 
ASC 1 - - - 1(100%) 
 
The above table shows seven cases of CNSC were negative (Figure-4) for p16. 
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GRAPH NO - 12 
PROPORTION OF POSITIVE TUMOUR CELLS BETWEEN CIN AND CARCINOMA 
 
GRAPH NO – 13 
PROPORTION OF POSITIVE TUMOUR CELLS AMONG CIN CASES 
 
 
85 
 
5.3.c STAINING INTENSITY OF p16 AMONG THE DIFFERENT GROUPS OF 
UTERINE CERVICAL LESIONS 
The staining intensity was scored between 0-3 and the results are shown in 
 table no-17, graph-14, 15. 
TABLE NO - 17 
STAINING INTENSITY OF p16 AMONG THE DIFFERENT GROUPS 
 
Interpretation of these data reveals that all adenocarcinoma cases (figure-28, 30, 32, 34, 
36), a case of Adenosquamous cell carcinoma (figure-38) and 73% cases of SCC have 
shown strong intensity.  
INTENSITY OF STAINING: n (%) CATEGORY 
0 (negative) 1+(weak) 2+(moderate) 3+(strong) 
CNSC 
7(77.7%) 1(11%) 1(11%) - 
CIN 1 - 4(40%) 5(50%) 1(10%) 
CIN 2 - 3(30%) 4(40%) 3(30%) 
CIN 3 - 2(20%) 3(30%) 5(50%) 
CIN 
CGIN - - - 1(100%) 
SCC - - 6(27%) 16(72.72%) 
AC - - - 6(100%) 
CA 
ASC - - - 1(100%) 
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GRAPH NO - 14 
STAINING INTENSITY OF p16 BETWEEN CIN AND CARCINOMA 
 
GRAPH NO - 15 
INTENSITY OF p16 STAINING AMONG CIN CASES  
 
87 
 
Hence p16 expression scoring was calculated by the product of percentage of positive 
tumour cell and intensity of grading and plotted in the following graph. The values 
obtained are 1, 2, 3, 4, 6 and 9. The value 4 is taken as cut off value. (Graph- 16, 17) 
GRAPH NO - 16 
p16 SCORE BETWEEN CIN AND CARCINOMA  
 
GRAPH NO - 17 
p16 SCORE AMONG CIN CASES 
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5.3.d p16INK4A STAINING IN CELLULAR REACTION PATTERN AMONG 
UTERINE CERVICAL LESIONS 
Various cellular reaction patterns were observed in our study which includes, 
cytoplasmic positivity in 16 cases, Nucleo-cytoplasmic positivity in 50 cases and one 
case showed nuclear positivity (Squamotransitional SCC i.e.figure-26) as illustrated in 
the following table no-18 
TABLE NO – 18 
 STAINING OF CELLULAR PATTERNS AMONG THE DIFFERENT GROUPS 
CIN CA 
TYPES CNSC CIN 
1 
CIN 
2 
CIN 
3 CGIN SCC AC ASC 
NEGATIVE  ( -VE) 7 - - - - - - - 
POSITIVE(+VE) 2 10 10 10 1 22 6 1 
CYTOPLASMIC 
POSITIVITY 
1 3 1 2 - 4 1 - 
NUCLEO:CYTOPLASMIC 
POSITIVITY 
1 7 9 8 1 17 5 1 
NUCLEAR POSITIVITY - - - - - 1 - - 
 
5.3.e PATTERNS OF p16INK4a STAINING EXPRESSION WITHIN 
EPITHELIUM OF DIFFERENT GRADES OF CIN 
Among the cervical intraepithelial neoplasia cases different patterns of staining 
was observed. The following table no- 19, graph-18 shows the percentage of cases 
showing patchy, diffuse basal and diffuse full thickness. (Figure-  6A,6B,8,10) 
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TABLE NO - 19 
PATTERN OF p16INK4a EXPRESSION IN DIFFERENT GRADES OF CIN 
CATEGORY N PATCHY 
n (%) 
DIFFUSE 
BASAL 
n (%) 
DIFFUSE FULL 
THICKNESSn (%) 
CIN 1 10 4(40) 6(60) - 
CIN 2 10 1(10) 7(70) 2(20) 
CIN 3 10 1(10) 4(40) 5(50) 
 
GRAPH NO - 18 
0
2
4
6
8
CIN 1 CIN 2 CIN 3
6
7
4
0
2
5
4
1 1
p16 PATTERN OF DISTRIBUTION WITH IN EPITHELIUM
Diffuse Basal Diffuse Full Thinkness Patchy
 
Above table concludes that p16 immunostaining positivity found to be both nuclear 
and/or cytoplasmic. The chronic non-specific cervicitis cases was predominantly 
negative for p16 (7/9) immunostaining. The  four parameters used for analysis of p 16 
immunostaining  includes  the proportion of positive tumour cells, intensity, pattern of 
p16 immunostaining with in the epithelium and cellular reaction pattern. Based on the 
four parameters it has been inferred that, there is an increase in progression of p16 
expression with increase in the grades of CIN and also from CIN to carcinoma. 
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5.4 STATISTICAL ANALYSIS 
pValue was calculated to find the significant correlation  of p16 overexpression 
within the sub groups of cervical lesions by statistical analysis.  
Test used - Fisher exact test and Extended Mantel-Haenszel chi square test for linear 
trend  
 pValue = 0.0001.  
From the tabulated data, p value was calculated. The value obtained was 
0.0001. Since the p value is smaller (<0.05), it is evident that rejecting the null 
hypothesis can be possible. This infers that p16INK4a expression can be directly 
correlated with the increasing grades of cervical intraepithelial neoplasia and 
carcinoma.   
 
 
 FIGURE- 1.Histology of normal cervical non-keratinizing squamous epithelium. 
The squamous cells show maturation from basal layer to the surface (H&E, 40X) 
 
FIGURE-2.Histology of normal cervix (IHC p16, 40X)-NEGATIVE STAINING 
 FIGURE-3.Chronic non-specific cervicitis composed of reactive atypia of squamous 
epithelium with inflammatory infiltrate in the stroma (H&E, 40x) 
 
FIGURE- 4.Chronic non specific cervicitis (IHC p16, 40X) – NEGATIVE STAINING 
 FIGURE- 5.Cervical intraepithelial neoplasia 1 composed of mild dysplasia confined 
to basal 1/3 of the epithelium (H&E, 40X) 
 
FIGURE- 6A.Cervical intraepithelial neoplasia 1(IHC P16, 40X) – DIFFUSE BASAL 
  
 
 
 
FIGURE – 6B, Cervical intraepithelial neoplasia 1 (IHC p16, 40X,) PATCHY 
DISTRIBUTION 
 FIGURE-7.Cervical intraepithelial neoplasia 2 composed of moderate dysplasia 
confined to basal 2/3 of the epithelium (H&E, 40X) 
 
FIGURE-8.Cervical intraepithelial neoplasia -2(IHC p16, 40X) 
 FIGURE-9.Cervical intraepithelial neoplasia 3 composed of severe dysplasia involving the 
full thickness epithelium (H&E, 40X) 
 
FIGURE-10.Cervical intraepithelial neoplasia 3 (IHC P16, 40X)- DIFFUSE FULL 
THICKNESS, NUCLEO: CYTOPLASMIC POSITIVITY 
 FIGURE- 11.Cervical glandular intraepithelial lesions composed of  dysplastic glands with 
intraluminal papillary projections (H&E, 10X) 
 
FIGURE-12. Cervical glandular intraepithelial neoplasia 
(IHC p16, SCANNER VIEW) 
 FIGURE-13.Squamous cell carcinoma with microinvasion characterized by tongue shaped 
malignant epithelial nest invading the stroma (H&E, 40X) 
 
FIGURE- 14. Squamous cell carcincoma with microinvasion (IHC p16, SCANNER VIEW) 
 FIGURE- 15.Large cell keratinizing squamous cell carcinoma characterized by malignant 
keratin pearl. (H&E, 40X) 
 
FIGURE- 16.Large cell keratinizing squamous cell carcinoma  (IHC p16, 40X) 
 FIGURE- 17.Large cell Non keratinizing Squamous cell Carcinoma composed of irregular 
nest of large malignant cells (H&E, 40X) 
 
FIGURE-18. Large cell non keratinizing squamous cell carcinoma (IHC p16, 40X) 
 FIGURE-19. Small cell Non keratinizing Squamous cell Carcinoma composed of sheets of 
small malignant cells(H&E, 40X) 
 
FIGURE- 20.Small cell non keratinizing squamous cell carcinoma (IHC p16, 40X) 
 FIGURE- 21.Basaloid squamous cell carcinoma composed of nests of small basal type of 
squamous cell with peripheral palisading. (H&E, SCANNER VIEW) 
 
FIGURE-22. Basaloid squamous cell carcinoma (IHC p16, 40X) 
FIGURE- 23.Papillary Squamous cell carcinoma composed of fibrovascular core lined by 
squamous epithelium resembles CIN (H&E, 40X) 
 
FIGURE- 24. Papillary squamous cell carcinoma (IHC p16, 40X) 
 FIGURE- 25, Squamotransitional cell carcinoma composed of papillary architecture  
with fibrovascular cores lined by a multi-layered, atypical epithelium resembling CIN3 
(H&E, SCANNER VIEW) 
 
FIGURE- 26.Squamotransistional cell carcinoma (IHC p16, 40X) – NUCLEAR 
POSITIVITY 
 FIGURE-27. Villoglandular Adenocarcinoma composed of fronded growth of thick or  
thin papillae, which are covered by endocervicaltype of epithelium.(H&E, 40X) 
 
 
FIGURE-28. Villoglandular adenocarcinoma (IHC p16, 40X) – CYTOPLASMC 
POSITIVITY 
 FIGURE- 29.Clear cell adenocarcinoma composed of clear cells or hob nail cells arranged in 
solid pattern (H&E, 40X) 
 
FIGURE- 30.Clear cell adenocarcinoma (IHC p16, 40X)-STRONG INTENSITY OF 
STAINING 
 FIGURE- 31.Endocervical adenocarcinoma (grade 2) composed of complex  
malignant glands lined by tall columnar cells with hyperchromatic nuclei. There is 
eosinophilic granular cytoplasm  and loss of mucin. (H&E, 40X) 
 
FIGURE- 32.Endocervical adenocarcinoma (GRADE 2) (IHC p16, 40X)) 
 FIGURE- 33.Poorly differentiated Endocervical Adenocarcinoma composed of sheets 
of malignant cells arranged in ill-defined glandular pattern (H&E, 40X) 
 
FIGURE- 34.Poorly differentiated endocervical adenocarcinoma (IHC p16, 40X) 
 FIGURE- 35.Endometrioid Adenocarcinoma composed of complex glands that are  
linedby endometrioid-type epithelium with stratified nuclei and minimal intracytoplasmic 
mucin. (H&E, 40X) 
 
FIGURE- 36.Endometroid adenocarcinoma (IHC p16, 40X) 
 FIGURE-37.Adenosquamous cell carcinoma composed of mixture of malignant 
glandular and squamous epithelial elements (H&E, 40X) 
 
FIGURE-38. Adenosquamous cell carcinoma (IHC p16, 40X) 
 FIGURE- 39.Adenoid squamous cell carcinoma composed of tubular or  
pseudoglandularpattern,polygonal cells  with glassy eosinophilic cytoplasm and focal 
squamous pearl formation.(H&E, 40X) 
 
FIGURE- 40.Adenoid basal carcinoma composed of nest of basaloid cells show focal gland 
formation (H&E, 40X) 
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DISCUSSION 
 
 In Thanjavur District, Tamil Nadu Health System Project - Pilot screening 
project for cervical cancer is an ongoing programme. Under this programme, 3198 
cervical biopsies specimen from various health centres has been received during the 
year 2013. Present study was carried out on 608 cervical neoplasms cases out of 3198 
cervical biopsies for a period of one year from January 2013 to December 2013 in the 
Department of Pathology, Thanjavur medical college.  
 In this study, Histologic subtyping of the neoplasms was assigned according to 
the WHO classification of tumours. Cervical neoplasms comprises 210 cases of CIN 1, 
38 cases of CIN 2, 27 cases of CIN 3, a case of CGIN, 318 cases of Squamous cell 
carcinoma, 9 cases of Adenocarcinoma and 5 cases of other epithelial tumours. 
 
INCIDENCE 
India contributes twenty seven percent (77,100) of the total cervical cancer 
deaths. Globally, age standardized death rate was about 9.5/10,000 population 
(WHO2009b), which is about one third of global cervical cancer death. In India years 
of life lost (YLL) were 936.3 in 2000 due to cervical cancer. This reflects that death 
rate due to cervical cancer in India is highest among the world84. 
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6.1 INCIDENCE, AGE GROUP AND BIOMARKER P16INK4A EXPRESSION IN 
CERVICAL NEOPLASMS IN THE PRESENT STUDY 
The following tables and graph shows the comparative study regarding 
incidence, age group and expression of p16 biomarker. The distribution of cervical 
neoplasms in different study groups is given table no-20 and graph-19. 
 
TABLE NO - 20 
DISTRIBUTION OF CERVICAL NEOPLASMS IN DIFFERENT STUDY 
GROUPS 
CERVICAL 
INTRAEPITHELIAL 
LESIONS 
INVASIVE 
CARCINOMA TOTAL STUDY 
(AUTHORS) 
NO. OF 
CASES % 
NO. OF 
CASES % 
NO. OF 
CASES % 
Grubb&janota et al53 49 50.5 48 49.5 97 100 
Klaes et al43 139 69.8 60 30.1 199 100 
Agoff et al54 169 76.1 53 23.8 222 100 
Nigatu et al55 358 13.4 2312 86.5 2670 100 
K gupta et al56 60 42.5 81 57.4 141 100 
 Van bogaert et al57 439 42.9 584 57 1023 100 
Present study 276 45.4 332 54.6 608 100 
 
 The incidence of cervical neoplasms varies from time to time and place to 
place in different parts of world. 
K gupta et al56in their study of 141cases of cervical lesions found 57.4% with 
invasive carcinoma and 42.5 % with intraepithelial lesions. 
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In another study by Van bogaert et al57 CIN 1, CIN 2, CIN 3 cases together 
constituted 42.9% and invasive carcinoma was 57%. 
The present study incidence correlates with Van bogaert et al57 and K gupta et 
al56 studies.   
 
GRAPH NO - 19 
 
AGE-WISE DISTRIBUTION PATTERN 
In this present study, age ranges from 21-90 years, with mean age of 46.8 years. 
In one end of the spectrum, two cases were reported as CIN1 at the age of 21 years and 
in other end, a case has been reported as carcinoma at the age of 90 years. The peak 
incidence of cervical intraepithelial neoplasms of cervix was seen in the fourth decade 
which was two decades earlier than that observed in the carcinoma group of patients. 
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Munhoz et al87studied 54 cases with the age ranges from 22 to 90 years and reported 
mean age  is 45.74 years, which correlates closely with our study  
 
MEAN AGE OF PRESENTATION OF CERVICAL NEOPLASMS 
Branca et al68 in their study found a mean age was 35.5 years and 59.2 years for 
the occurrence of both CIN and Carcinoma, in patients whose age ranged from 18-79 
years. In the present study, mean age of patients with CIN and Carcinoma was 39.7 
years and 52.61 years respectively with the range of 21-90 years. The present study is 
very close to Branca et al68study. (Table no-21, graph- 20)   
TABLE NO - 21 
RANGE AND MEAN AGE OF OCCURRENCE OF CERVICAL NEOPLASMS 
IN DIFFERENT STUDIES 
STUDY 
(AUTHOR) 
RANGE 
(YEARS) 
MEAN AGE 
(YEARS) 
CIN 
MEAN AGE (YEARS) 
CARCINOMA 
Branca et al68 18-79 35.5          59.2 
Present study 21-90 39.7 52.61 
 
Thus, the above table suggest that there is a window period of 10 years progression of 
CIN to carcinoma. As there is a long time interval for progression to malignancy, 
appropriate intervention strategies like screening with VIA/VILI or PAP smears 
examination in this intervening period helps in early diagnosis and management of 
cervical neoplasms. 
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GRAPH NO - 20 
 
6.2 CERVICAL INTRAEPITHELIAL NEOPLASMS 
The distribution of grades of CIN in various studies is given in table no-22, graph- 21, 
22. 
TABLE NO - 22 
DISTRIBUTION OF GRADES OF CIN IN VARIOUS STUDY GROUPS 
CIN 1 CIN 2 CIN 3 TOTAL 
STUDIES 
(AUTHORS) No. of 
cases 
% No. of 
cases 
% No. of 
cases 
% 
No. 
of 
cases 
% 
Murphy et al62 38 32.4 33 28.2 46 39.3 117 100 
Karcheva et al86 3 15.7 8 42.1 8 42.1 19 100 
Zhang et al58 157 54 70 24 65 22 292 100 
K Gupta et al56 35 58 15 25 10 17 60 100 
Present study 210 76 38 14 27 10 275 100 
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Zhang et al58. Reported 54%, 24%, 22% cases of CIN 1, CIN 2, CIN 3 
respectively out of 292 cases, whereas K gupta et al56 reported 58%, 25% and 17% of 
CIN 1, CIN 2 and CIN 3 out of 60 cases respectively. Murphy et al and karcheva et al 
also noted varied distribution in cervical intraepithelial neoplasms. 
In the present study CIN 1, CIN 2 and CIN 3 constituted 76%, 14% and 10% 
cases respectively. This comparative study reveals that CIN 1 lesion constituted the 
majority. 
 
 
GRAPH NO - 21 
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GRAPH NO – 22 
 
 
 
p16INK4aEXPRESSION 
Based on the four parameters ( percentage of positive tumour cells, intensity of 
staining, cellular pattern staining , pattern of staining within epithelium), the present 
study assessed the p16 immunostaining and observed that, with increasing grades of 
intra epithelial squamous neoplasia, the percentage of positivity and the intensity of p16 
staining also increased.  
Analysis of first parameter based on the (table no-16) it will endorse the 
percentage of positive tumour cells correlates directly with the CIN grading. Here, 60% 
of CIN 1 cases exhibit 1-5% (1+) tumour cell positivity, 80% of CIN 2 cases exhibiting                  
5-25%(2+) positivity whereas in 90% of CIN 3 cases 50% exhibiting 5-25%(2+) and 
40% exhibiting >25%(3+) positivity.  
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Analysis of intensity of staining among the different groups based on the (table 
no-17) 50% cases of CIN 1 lesions show moderate intensity(2+), among CIN 2 lesion 
40% exhibits moderate intensity(2+) and 30% exhibits strong intensity, in CIN 3 
lesions 50% of cases express strong(3+) positivity. Hence the intensity of staining also 
correlates directly with the increasing grades CIN lesions.  
Based on the distribution of p16 expression with in epithelium, CIN cases were 
graded as diffuse full thickness, diffuse basal and patchy. Among CIN 1cases, 4 cases 
showed patchy staining, 6 cases showed diffuse basal staining, In CIN 2 cases, 
predominantly diffuse basal pattern was observed (7/10). In CIN 3 cases, 50% cases 
expressed diffuse full thickness staining. when compared with Kumar et al study and 
Lulinhu et al showed that CIN 1 cases expressed predominantly patchy staining 
whereas CIN3 exhibited  diffuse full thickness staining pattern. 
 Hence the above factors can be taken for standardization of p16 
immunostaining as supported by other studies done by Kumari et al42, Klaes et al43 and 
R gupta et al44 
 
6.3 CERVICAL GLANDULAR INTRAEPITHELIAL NEOPLASIA 
Murphy et al62 studied 5 cases of CGIN out of 153 cases, where Karcheva et 
al86reported a case of CGIN out of 54 case. From the present study a case of CGIN was 
reported out of 608 cases. 
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Mean age of presentation –CGIN 
Kurian and Nafussi et al69 studied 27 cases of CGIN and reported mean age for low 
grade CGIN was 39 years whereas Plaxe and saltzstein et al64 conducted study in a 
large series of 5845 patients and found that mean age of CGIN was 38.8 years. Fadwa 
J.et al86 studied 167 cases of cervical carcinoma and the age incidence was 58 years. 
But in this study, single case of CGIN was reported and the age was 55 years which 
coincides with the age group of Fadwa J. et al86(table no-23) 
TABLE NO - 23 
MEAN AGE FOR CGIN IN DIFFERENT STUDIES 
STUDY (AUTHOR) MEAN AGE(YEARS) 
Kurian and nafussi et al69 39 
Brown and wells et al70 36.9 
Plaxe and saltzstein et al64 38.8 
Fadwa J.et al86 58 
Present study 55 
 
p16ink4a in cervical glandular intraepithelial neoplasia 
The p16 immunostaining showed strong intensity of staining (figure-12).  The 
distinction of carcinoma in situ from benign mimics, especially tubo-endometrial 
metaplasia, endometriosis, and micro glandular hyperplasia is difficult. Here, p16 plays 
a major role by differentiating the dysplastic cells45. 
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In this study, a case of CGIN expressed >25% positive tumour cells with p16, 
similar results were found in Negri et al80, Karcheva et al86, Murphy et al study. In 
klaes et al43 reported 85% positivity. The intensity of staining showed strong diffuse 
nuclear cytoplasmic positivity. 
6.4 CERVICAL CARCINOMA 
The distribution of cervical carcinoma in different study groups is given table no-24, 
graph-23. 
TABLE NO - 24 
DISTRIBUTION OF CERVICAL CARCINOMA IN DIFFERENT STUDY 
GROUPS 
Squamous 
cell 
carcinoma 
Adenocarcinoma Adenosquamous 
cell carcinoma Total 
Study(author) 
No. 
of 
cases 
% No. of 
cases 
% No. of  
cases 
% 
No. 
of 
cases 
% 
Balkachewnigatu 
et al55 2182 94.3 104 4.4 26 1.1 2312 100 
K gupta et al56 75 92.5 3 3.7 3 3.7 81 100 
Takaakisano et 
al59 39 72.2 9 16.6 6 11 54 100 
Morelva et al76 62 76.5 19 23.4 ND 81 100 
Present study 318 95.8 9 2.7 4 1 331 100 
 
 
 
101 
 
 
 
The invasive carcinoma of cervix is classified into three main group’s namely 
Squamous cell carcinoma, adenocarcinoma and other epithelial tumours. 
Balkachew nigatu et al55, in their study found 94.3% (2182) of SCC, 4.4% (104) 
of Adenocarcinoma and 1.1% (26) of Adenosquamous cell carcinoma in total number 
of 2312 cases. 
K gupta et al56also had similar observations in their study with 92.5% of SCC a, 
3.7% of Adenocarcinoma and 3.7% of Adenosquamous cell carcinoma. 
Takaakisano et al59 and Morelva et al76 also found varied incidence in 
carcinoma of cervix. 
In the present study, 95.8% (318) cases of SCC group, 2.7% (9) cases of 
Adenocarcinoma group and 1 %( 4) case of Adenosquamous cell carcinoma. This is in 
accordance with other studies, where SCC is the predominant histological type. 
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GRAPH NO - 24 
 
DISTRIBUTION OF PATIENTS ACCORDING TO AGE GROUP: 
COMPARISON OF PATIENTS ACCORDING TO INDIVIDUAL AGE-GROUP 
DISTRIBUTION 
Comparison of cervical cancer patients among individual age groups between 
the present study at Thanjavur and a cancer registry in AIIMS75 showed similar 
incidence trends with respect to age group. In both studies majority of cases belonged 
to 50-59 years age group followed in descending order by 40-49 years, 60-69 years, 30-
39 years and 70-79 years.(table no-25, graph-24). 
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TABLE NO - 25 
AGE WISE INCIDENCE PATTERN OF INVASIVE CARCINOMA IN 
VARIOUS STUDIES 
SHANTHA 
V60 
WHAI ET 
AL67 
AIIMS 75 
PRESENT 
STUDY AGE 
(YEARS) 
NO. OF 
CASES % 
NO. OF 
CASES % 
NO. OF 
CASES % 
NO. OF 
CASES % 
20-29 93 9 38 5.5 22 2.4 5 1.5 
30-39 299 29.2 170 24.6 106 11.8 28 8.4 
40-49 384 37.5 267 38.7 233 25.9 84 25.3 
50-59 176 17.3 158 22.9 245 27.2 107 32.2 
60-69 63 6.2 51 7.4 223 24.8 81 24.3 
70-79 8 0.7 3 0.4 69 7.6 23 6.9 
80-89 2 0.1 - - - - 3 0.9 
90-99 - - - - - - 1 0.3 
Total 1025 100 689 100 898 100 332 100 
 
• All the fact shows that cervical neoplasms are common in 5th to 7th decades. 
These findings are in accordance with already existing fact that cervical cancer 
is due to persistence of high risk human papilloma virus. Thus persistence of integrated 
HPV infection results in carcinogenic transformation. 
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GRAPH NO - 25 
 
In this study vast majority of patients 81% (272) belonged to 5th to 7th decade of 
life. This is in line with AIIMS data (78%) 75. 
C.S. Herrington et al81 reports that peak age incidence for invasive carcinoma is 
60-64 years. 
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TABLE NO - 26 
AGE GROUP WITH MAXIMUM INCIDENCE OF INVASIVE CARCINOMA 
CERVIX IN DIFFERENT STUDY GROUP 
STUDIES 
 (AUTHORS) 
AGE GROUP WITH MAJORITY OF CASES 
(YEARS) 
Shantha V60 40-49 
Chaudhary et al61 41-50 
Wahi et al67 45-54 
AIIMS75 50-59 
Present study 50-59 
 
From the above data it has been inferred that invasive carcinoma occurs 
predominantly in the age group of 50-59 years.  Similar findings were seen in studies 
done by Wahi et al67 and AIIMs cancer registry75.(table no-26) 
Shantha V60 et al reported that maximum number of patients belonged to 40-49 
years. However Chaudhary et al61 showed majority of cases belonged to 41-50 years 
age group similarly. 
6.5 SQUAMOUS CELL CARCINOMA 
Squamous cell carcinoma constitutes 80-90% on cervical carcinoma. It is graded into 
three grade based on Modified Broder’s grade. Distribution of modified Broder’s 
grading of squamous cell carcinoma in different study groups is given in table no-27, 
graph-25, 26. 
.  
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TABLE NO - 27 
DISTRIBUTION OF MODIFIED BRODER’S GRADING OF SQUAMOUS 
CELL CARCINOMA IN DIFFERENT STUDY GROUPS 
GRADE 1 GRADE 2 GRADE 3 TOTAL 
STUDY 
(AUTHOR) NO. 
OF 
CASES 
% 
NO. 
OF 
CASES 
% 
NO. 
OF 
CASES 
% 
NO. 
OF 
CASES 
% 
Grubb &janota et 
al53 11 29.9 26 54.2 11 22.9 48 100 
Mathur et al77 66 23.4 165 58.5 51 18.1 282 100 
K gupta et al56 13 17.3 55 73.3 7 9.3 75 100 
Present study 48 15.9 242 80.3 11 3.7 301 100 
 
K gupta et al56in their study of 75 cases of conventional SCC reported 
13(17.3%), 55(73.3%) and 7(9.3%) cases of well, moderately and poorly differentiated 
types respectively. 
Grubb & janota et al53and Mathur et al77study also showed moderately 
differentiated SCC being the predominant histological type. 
In this present study, moderately differentiated carcinoma constitutes 80 %( 242) 
whereas 15.9% (48) of well differentiated and 3.7 %( 11) cases of poorly differentiated 
SCC were observed. 
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GRAPH NO - 26 
 
MEAN AGE FOR SCC IN DIFFERENT STUDIES  
Several studies such as Mckuster me et al65, Plaxe and saltzstein et al64, Geok 
Chin Tan et al63 have reported that the mean age for SCC was 52 years which is in 
close proximity to our study.(table no-28, graph-27) 
TABLE NO - 28 
MEAN AGE FOR SCC IN DIFFERENT STUDIES  
STUDIES (AUTHOR) MEAN AGE (YEARS) 
Mckuster me et al65 52 
Plaxe and saltzstein et al64 52 
Geok Chin Tan et al63 52.5 
Nigatu et al55 48.3 
Present study 52.6 
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p16 EXPRESSION IN SQUAMOUS CELL CARCINOMA 
In the present study, analysis of cellular patterns of p16 staining (nuclear: 
cytoplasmic staining, cytoplasmic staining, and nuclear staining) in SCC (22 cases) 
showed 4 cases of cytoplasmic positivity (1- LCKSCC, 2-LCNKSCC, 1-SCNKSCC), 
17 cases expressed nuclear: cytoplasmic positivity (4- SCC MI, 1-LCKSCC, 9-
LCNKSCC, 1-SCNKSCC, 1-basaloid, 1-papillary) and a case of Squamotransitional 
carcinoma expressed nuclear positivity.  
Analysis of intensity of staining in SCC 72.72% cases show strong (3+) 
positivity and 27% shows moderate (2+) positivity ( single case of SCC with 
microinvasion, LCKSCC, LCNKSCC, Squamotransitional SCC and 2 cases of 
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SCNKSCC) and percentage of positive tumour cell showed 95.45% cases of SCC 
expresses >25% positive tumour cells (Squamotransitional SCC-5-25%). 
 Hence above factors can be taken for standardization of p16 immunostaining as 
also supported by other studies such as Kumari et al42, Klaes et al43 and R gupta et al44. 
The p16 immunostaining of SCC in various grades are depicted in figure - 16, 
18, 20.  
6.6 SQUAMOUS CELL CARCINOMA WITH MICROINVASION AND ITS 
VARIANTS 
SQUAMOUS CELL CARCINOMA WITH MICROINVASION  
In the present study, 14 cases (4.2%) were reported out of 332 cancer cases 
where Fadwa et al86reported a case out of 167 cases. 
Costa et al92 reported median age is 37 years with in the range of 20-69 years in 
230 total cases whereas mean age is 47 years with in the range of 33-67 years in this 
study. 
Biomarker p16 expression study was done on four cases and all cases showed 
>25% positive tumour cells, nucleo: cytoplasmic postivity and strong intensity of 
staining, expect one case showed moderate intensity.   
 
PAPILLARY SQUAMOUS CELL CARCINOMA 
Microscopically, the tumour composed of thin or broad fibrovascular septa 
lined by multi-layered squamous epithelium.  
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Fadwa et al86 reported a case(0.6%) out of 167 total cases and in the present 
study, 3 cases (0.9%) of papillary squamous cell carcinoma out of 608 cases were 
reported  which has a similar incidence of Fadwa et al study. 
Michal odida et al91 studied 20 cases of papillary SCC and found the age ranges 
from 22 to 70 years with mean age of 46.6years which go in line with the mean age of 
45 years in the present study. 
Immunostaining with p16 biomarker express strong intensity, >25% positive 
tumour cells and showed Nucleo: cytoplasmic positivity. (Figure-24) 
 
BASALOID SQUAMOUS CELL CARCINOMA 
This is a rare variant of SCC with an aggressive nature, which has the 
characteristic histologic features of Basaloid cells arranged in nests, groups, trabeculae 
and lobules with peripheral palisading. In the present study 2 cases of Basaloid 
squamous cell carcinoma was reported, whose age is 50 & 60 years.  
IHC staining with p16 showed strong intensity of staining, >25% positive 
tumour cells and showed nuclear: cytoplasmic positivity. (Figure-22) 
 
SQUAMOTRANSITIONAL CELL CARCINOMA 
It’s a rare variant tumour which is potentially aggressive; it occurs 
predominantly in the age group of post-menopausal women89. Mani Anand et al90 
studied 9 cases of Squamotransitional cell carcinoma and the age group of patients in 
that study range from 35 to 75 years. This study reported a case and its age is 45 years 
which falls within this age group. 
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p16INK4a immunostaining showed moderate intensity of staining, 5-25% positive 
tumour cells and nuclear positivity. (Figure-26) 
 
ADENOID SQUAMOUS CELL CARCINOMA 
A single case was noted and the age was 27 years in the present study. Horie Y 
et al93 reported the similar case in cervix at 60 years. 
 
6.7   ADENOCARCINOMA 
 The distribution of adenocarcinoma and its variants cases in various studies is given in 
table no-29, graph-28. 
TABLE NO - 29 
DISTRIBUTION OF ADENOCARCINOMA AND ITS VARIANTS IN 
VARIOUS STUDIES 
Studies 
(author) 
Endocervical 
AC 
Clear cell 
AC 
Endometrioid 
AC 
Villoglandular 
AC 
Saad et al72 65 - 10 - 
Morelva et al76 8 - 5 3 
Present study 6 1 1 1 
 
Saad et al72in their study of 75 cases of Adenocarcinoma found 65 cases of 
endocervical and 10 cases of Endometroid AC whereas Morelva et al76 in their study of 
16 cases of Adenocarcinoma found 8, 5 and 3 cases of Endocervical, Endometroid and 
Villoglandular types respectively. 
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In the present study, Endocervical Adenocarcinoma being predominant, 
constitutes about 67%(6) whereas other variants like clear cell Adenocarcinoma, 
Endometroid Adenocarcinoma and Villoglandular Adenocarcinoma constitutes 11%(1) 
each. 
GRAPH NO - 28 
 
 
The mean age for adenocarcinoma in different studies is given in table no-30, graph-29. 
TABLE NO - 30 
MEAN AGE FOR ADENOCARCINOMA IN DIFFERENT STUDIES 
STUDY (AUTHORS) MEAN AGE (YEARS) 
Kurian and nafussi et al69 48 
Altecruse et al66 38 
Saad et al72 45 
Nigatu et al55 48.5 
Present study 53 
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The mean age of Adenocarcinoma of cervix has shown to be 48 years in a study 
by Kurian and Nafussi et al69 and 45 years in a study by saad et al72 .In the present 
study the mean age is 53 and closely correlates with kurain and nafussi study and 
Nigatu et al55 
GRAPH NO - 29 
 
 
VILLOGLANDULAR ADENOCARCINOMA  
WHO18 states that there is a possible link with occurrence of Villoglandular 
adenocarcinoma and oral contraceptives usage. 
Jones et al study states that it occurs in women aged between 23 to 57 years and 
in the present study a case of Villoglandular Adenocarcinoma in a 60 years old lady 
was documented. 
 
INVASIVE ENDOCERVICAL ADENOCARCINOMA 
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Fadwa j et al studied 12 cases of endocervical Adenocarcinoma and found that 
mean age of occurrence is 48 years, similar mean age group of 50 years among 6 
endocervical adenocarcinoma cases was observed in the present study. 
 
 
 
ENDOMETRIOID ADENOCARCINOMA 
Endometroid adenocarcinoma resembles endometrial adenocarcinomas so 
closely. The age group of presentation in the present study was 50 yrs. 
 
CLEAR CELL ADENOCARCINOMA 
Histologically the tumour cells are clear or hobnail in appearance. Its peak 
frequency occurs in bimodal age groups, that is in young age group (DES exposure) 
and in postmenopausal age group18. Here, a case of clear cell adenocarcinoma in 62 
years old female was reported.  
 
p16INK4a EXPRESSION 
All cases of adenocarcinoma expressed 100% positivity in both intensity and 
percentage of positive cells; similar results were found in Negri et al80, Karcheva et 
al86, Murphy et al study. In klaes et al43 showed 85% positivity. 
Among 6 cases of adenocarcinomas, one case of Villoglandular type expressed 
cytoplasmic positivity, and others showed nuclear: cytoplasmic positivity 
 
6.8 OTHER EPITHELIAL TUMOURS 
ADENOSQUAMOUS CELL CARCINOMA  
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Adenosquamous cell carcinoma comprises 3–5% of cervical tumours. Cell of 
origin is columnar cells of the cervical mucosa. This reserve cells simultaneously 
differentiate towards columnar and squamous cells. Hence the tumour contains an 
admixture of histologically malignant squamous and glandular cells which has a 
significantly worse prognosis than other glandular lesions. 
TABLE NO - 31 
INCIDENCE OF ADENOSQUAMOUS CELL CARCINOMA IN VARIOUS 
STUDIES 
STUDIES (AUTHOR) PERCENTAGE(N) 
K gupta et al56 3.7%(3) 
Balkachewnigatu et al55 1.1%(26) 
Present study 1.2%(4) 
 
From this comparative study (table no- 31), our incidence of Adenosquamous 
carcinoma correlates with Balkachewnigatuetal55 study. The mean age is 50 years in 
our study. 
 Immunostaining with p16 showed strong intensity of staining, >25% positive 
tumour cells and Nucleo: cytoplasmic positivity. (figure-38) 
ADENOID BASAL CARCINOMA  
It accounts for< 1 % of cervical carcinoma6. In this present study, it constitutes 
0.17% i.e. <1%.  
117 
 
Baggish and Woodruff 74 et al studied 100 cases of adenoid basal carcinoma and 
reported that mean age is ≥45 years of age (post-menopausal age group). 
WHO18 reports Adenoid basal carcinoma patients age group is usually more 
than 50 years.  Similar age group incidence also found in our study i.e. 55 years. 
 
 
6.9  BIOMARKER p16INK4a IMMUNOEXPRESSION IN CERVICAL 
NEOPLASMS 
Here, the main diagnostic role of immunohistochemistry in evaluation of 
cervical neoplastic lesions is to distinguish dysplasia from benign lesions and to 
evaluate the  cauterised margins.  
Grading the dysplasia remains an issue for morphological criteria. However in 
the histologic diagnosis of these reports shows repeated absence of interobserver 
reproducibility. 
There is wide array of biomarkers which have been used in diagnosis of cervical 
neoplasms. Objective biomarkers could result in improvement of diagnostic specificity 
as a result of clear identification of accurate dysplastic cells.     
One of the ideal biomarker used extensively is p16, which is a tumour 
suppressor protein located in the nucleus, so nuclear staining in IHC is expected. But 
both nucleus and cytoplasm stain positively in dysplasia has been observed possibly 
because of post transcriptional modification or over production of p16 overflowing into 
the cytoplasm. Various research papers supported that there is an up regulation of p16 
in HPV related cervical lesions. Hence this study used this marker as a diagnostic tool. 
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The following table no- 32, graph-30, compares the present study with the 
recent studies done on p16 expression that is number of positive cases in the total 
number of cases in cervical lesions. 
 
TABLE NO - 32 
STUDIES PUBLISHED ON p16INK4A EXPRESSION 
Studies(
years) 
Normal 
%(n) 
CIN 1 
%(n) 
CIN 2 
%(n) 
CIN 3 
%(n) 
CGIN 
%(n) 
SCC 
%(n) 
AC 
%(n) 
Klaes et 
al43 
(2001) 
27 
(13/48) 
85 
(40/47) 100(32/32) 
100 
(60/60) ND 
98 
(52/53) 
85 
(6/7) 
Murphy 
et al62 
(2003) 
0 
(0/21) 
100 
(38/38) 
100 
(33/33) 
98 
(45/46) 
100 
(5/5) 
100 
(8/8) 
100 
(2/2) 
Karchev
a et al86 
(2007) 
0 
(0/13) 
66 
(2/3) 
87 
(7/8) 100(8/8) 
100 
(1/1) 
100 
(16/16) 
100 
(5/5) 
Gupta et 
al44 
(2007) 
10 
(2/20) 
50 
(10/20) 
60 
(12/20) 
70 
(14/20) ND 
95 
(19/20) ND 
Lesniko
va et 
al47 
(2009) 
ND 72.3 (180/249)
91 
(212/233) 
98.3 
(178/181) ND 
98.5 
(131/133) ND 
Supriya 
et al22 
(2010) 
0(0/15) 100 (15/15) 
100 
(15/15) 100(3/3) ND 
100 
(15/15) ND 
Kumari 
et al42 
(2013) 
25(4/16) 62.6 (10/16) 75(12/16) 
81.2 
(13/16) ND 
100 
(16/16) ND 
Present 
study 
22.2 
(2/9) 
100 
(10/10) 100(10/10) 
100 
(10/10) 
100 
(1/1) 
100 
(23/23) 
100 
(6/6) 
ND - Not done.  
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From the above data all precancerous lesions and the carcinomas have shown 
100% positivity for p16 in our study.  In comparison with other studies like Supriya et 
al (100%)22 and Murphy et al(100%)62 that as well documented similar results. 
Since p16 immunostaining positivity directly correlates with the HPV induced 
morphological changes and expected 0 % positivity in chronic non-specific cervicitis 
but found that 2 /9 cases (22%) showed p16 positivity. Likewise, few other studies like 
Kumari et al42 (25%), Gupta et al44 (10%) and Klaes et al43 (27%) have also observed 
p16 positivity in chronic non-specific cervicitis. Such cases were reviewed and 
classified into CIN 1. It infers difficulty to diagnosis the subtle histopathological 
features only by analysing the haematoxylin and eosin stained slides as either cervicitis 
or CIN. Hence, p16 immunostaining can serve as diagnostic tool assisting the difficult 
cases to diagnose correctly. 
Murphy et al.62 performed p16 immunostaining in 154 cases and found negative 
staining in all normal cervical tissue and 100% positivity in all cervical neoplasm 
expect a case of CIN 3. In this study some CIN1cases showed nuclear staining whereas 
in our study a case of Squamotransitional cell carcinoma showed nuclear staining. The 
study by Murphy et al. found precancerous lesions showed predominantly cytoplasmic 
pattern staining. All cancerous lesions including both squamous cell carcinoma and 
adenocarcinoma showed strong nuclear and cytoplasmic staining.  
Supriya et al22studied 63 cases with immunostaining markers p16 and MIB1. 
All normal cervical tissue including normal epithelium, metaplastic, endocervical 
reactive and inflammatory regions showed negative p16 immunostaining whereas all 
precancerous and cancerous lesions showed 100 % positivity. 
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The present study showed similar results to Murphy et al62and Supriya et al22 
study. 
Gupta et al44 studied 100 cases, in that 18/20 cases of normal cervical 
epithelium showed negative staining with anti-p16 antibody. Intraepithelial neoplasms 
showed progressive increase in expression with p16 immunostaining. In his study CIN 
1, CIN 2, CIN 3 and SCC cervical lesions expressed p16 positivity of about 50%, 45%, 
55% and 90% showed a strong nuclear or Nucleo : cytoplasmic positivity respectively. 
Whereas Kumari et al42 study showed p16 positivity of 25% CNSC, 62.2% CIN 1, 75% 
CIN 2, 81% CIN 3 and 100% SCC. 
Observed statistical analysis in this study showed p value <0.05 which was 
considered very significant and signifies p16 is ideal marker for cervical dysplasia. 
Thus this study highlights the increasing expression of p16INK4a in higher grades 
of CIN and cervical carcinoma concurrent with many studies (Table - 32).This finding 
emphasizes the role played by this marker in early carcinogenesis and progressive 
accumulation of nuclear protein as the tumour progresses. The association of this 
marker seen in high grade CIN and cervical carcinoma suggests their association with 
infection by high risk HPV types. 
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CONCLUSION 
• Uterine cervical neoplasms accounts for 19% of total number of cervical 
biopsies received at Thanjavur Medical College & Hospital, Pathology 
Department, for a period of one year from January 2013 to December 2013.  
• The incidence of uterine cervical carcinoma is 10.41%, while cervical 
intraepithelial neoplasm is 8.44%, with a ratio of 1.23:1. 
• Most of the patients age group with cervical carcinoma (27.52%) fall under 5th 
decade of life. 
• Majority of Cervical intraepithelial neoplasms patients (45.6%) falls in the age 
group between 30-39 years which is two decades earlier than the cervical 
carcinoma patients (32.13%) age group (50-59 years). 
• The mean age for cervical intraepithelial neoplasms is 39.8 years and cervical 
carcinoma is 52.61 years. This confirms window period of ten years to 
intervene by screening tests for early detection and treatment. It prevents the 
progression of disease process from cervical intraepithelial neoplasia to cervical 
carcinoma. 
• CIN 1 constitutes 77% of total cervical intraepithelial neoplasia cases. 
• Squamous cell carcinoma constitutes 95.8% in the total cervical cancer cases 
which is the most common subtype. 
• In squamous cell carcinoma, large cell non keratinizing squamous cell 
carcinoma   (Grade 2) predominate the profile based on grade of differentiation. 
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• Immunostaining with p16ink4a was performed on 69 cases of cervical lesions, in 
that 9 cases of chronic non-specific cervicitis were taken as control. 60 cases 
were randomly selected from 608 cases, which constitute 10% of the sample 
size. Cervical neoplasms showed 100% positivity.  
• Four parameters were used to score the p16 expression in cervical neoplasm and 
found there is progressive increase in the percentage of positive tumour cells 
and intensity of staining from CIN to cervical carcinoma. 
•  Thus, overexpression of p16 immunostaining serves as a potential diagnostic 
tool in cervical neoplasms. 
The present study signifies the usefulness of an ideal immunomarker 
p16INK4a as a diagnostic tool and emphasizes the importance of incorporating the HPV 
cotesting (p16INK4a) in the primary screening programme. Due to the incorporation 
HPV cotesting, there is a beneficiary effect on both the patient and less costly to the 
health care system.   
“Low cost – point of care screening test for the general population and a 
Government subsidized global vaccination programme” if followed, it is entirely 
conceivable that women will no longer die from cervical cancer in the near future. 
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LIST OF ABBREVIATIONS 
1. PBCR – Population Based Cancer Registry 
2. HBCR – Hospital Based Cancer Registry 
3. HPV- Human Papilloma Virus 
4. SCJ- Squamo-Columnar Junction 
5. TNHSP- Tamil Nadu Health System Project 
6. VIA- Visual Inspection with Acetic acid 
7. VILI – Visual Inspection with Lugol’s Iodine 
8. CIN – Cervical Intraepithelial Neoplasia 
9. H&E – Haematoxylin and Eosin 
10. IHC – ImmunoHistoChemistry  
11. TMCH – Thanjavur Medical College and Hospital 
12. CNSC – Chronic Non Specific Cervicitis.  
13. LSIL – Low-grade Squamous Intraepithelial Lesion  
14. HSIL – High-grade Squamous Intraepithelial Lesion  
15. WHO – World Health Organisation 
16. SCC – Squamous Cell Carcinoma 
17. LCKSCC – Large Cell Keratinizing Squamous Cell Carcinoma 
18. LCNKSCC – Large Cell Non  Keratinizing Squamous Cell Carcinoma  
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19. SCNKSCC – Small Cell Non  Keratinizing Squamous Cell Carcinoma 
20. AC – Adeno Carcinoma 
21. HPF – High Per Field 
22. HR-HPV – High Risk - Human Papilloma Virus 
23. DNA – Deoxyribo Nucleic Acid 
24. AJCC – American Joint Committee on Cancer 
25. CA – Carcinoma  
26. CK – Cytokeratin  
27. EMA – Epithelial Membrane Antigen  
28. pRB – Retinoblastoma protein 
29. N:C – Nucleo: Cytoplasmic  
30. ER – Estrogen Receptor. 
31. PR  - Progesterone Receptor 
32. CEA – Carcino Embryonic Antigen 
33. CAM 5.2 – Cytokeratin 8,18, Low Molecular Weight 
34. ACS – American Cancer Society, 
35. ASCP – American Society for Clinical Pathology. 
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                                                               ANNEXURE-I 
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ANNEXURE-II 
 
                                           HAEMATOXYLIN AND EOSIN STAIN 
 
PREPARATION OF SOLUTION: 
 
HARRIS HAEMATOXYLIN 
 
  Distilled water: 1000ml  
  Ammonium alum: 100g  
 Absolute ethyl alcohol: 50ml  
Mercuric oxide: 2.5g  
 100g of ammonium alum dissolved in 1000ml of distilled water by heatingand 
shaking at 60°C. 
 Add solution of 5g of haematoxylin in 50ml of ethyl alcohol and bring rapidly 
to boil. 
 When it begins to boil, remove from flame. 
 Add 2.5 g of mercuric oxide. 
  Mix by swirling gently.  
 
 PREPARATION OF EOSIN STAIN 
 
Eosin Y: 1 g.  
 Distilled water:  20ml 
 95% ethanol: 80ml  
 Glacial acetic acid: 0.2ml  
 Dissolve 1 gm of eosin Y in 20ml of water,and then add 80 ml of 95% ethyl 
alcohol and 0.2 ml of glacial acetic acid. 
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Procedure:  
 
1. Bring the sections to water  
2. Dip in Harris haematoxylin for 15 minutes.  
3. Rinse in tap water.  
4. Differentiate in 1% acid alcohol-3-4 quick dips.  
5. Wash in tap water briefly.  
6. Dip in ammonia water or saturated lithium carbonate until the sections are blue.  
7. Wash in running tap water for 10-20 minutes.  
8. Stain with eosin for 15 seconds to 2 minutes depending on the age of the eosin 
and the depth of counter stain.  
9. Rinse in tap water.  
10. Dip in 95% alcohol  
 
11. 3 changes in absolute alcohol.  
 
12. Xylene – 2 changes.  
 
13. Mount in DPX mountant. 
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ANNEXURE-III 
IMMUNOHISTOCHEMISTRY 
 
PREPARATION OF SOLUTIONS:  
Citrate buffer solution- antigen retrieval solution 
Trisodium citrate: 2.94 gm  
1 N Hydrochloric acid: 5ml  
Distilled water: 1000 ml  
Required pH is 6.0, which are obtained by titration with 1N HCl.  
Tris Buffer Saline (TBS) - wash buffer  
Sodium chloride: 8gms  
Tris (hydroxymethylamine): 0.605gms  
1 N Hydrochloric acid: 4 ml  
Distilled water: 1 litre  
Required pH is 7.6, which are obtained by titration with 1N HCl.  
Preparation of chrom alum coated slides:  
Potassium dichromate: 50 mgs  
Gelatin: 300 mgs  
Distilled water: 100 ml 
Potassium dichromate is added to distilled water and then boiled to 60◦C. Gelatin is 
then added slowly to it. Glass slides are then dipped in this solution and dried 
overnight.  
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After taking the required sections onto the coated slides, it is baked overnight at 45°C 
in the autoclave. The next day, the slides are taken for the procedure.  
ANTIGEN RETRIEVAL:  
The slides are arranged in a metal racket and placed in citrate buffer inside the pressure 
cooker, and allowed to boil up to three whistles. 
 
Procedure: 
 
1.Dewax the section in xylene(15 minutes each, 2 changes) and then in decreasing 
grades of alcohol then finally bring the sections to running tap water followed by 
distilled water. 
2. Antigen retrieval using TBS by pressure cooker method  
3. Cool to room temperature in running tap water for 20 minutes.  
4. Wash in TBS -2 changes for 5 minutes each.  
5. Drain and cover the sections with peroxidise block (endogenous peroxidise blocking 
agent) for 15 minutes.  
6. Wash in TBS -2 changes for 5 minutes each.  
7. Drain and cover the tissue sections with power block for 15 minutes  
8. Drain and blot the excess power block.  
9. Cover the sections with the respective primary antibody for 90 minutes.  
10. Wash in TBS -2 changes for 5 minutes each.  
11. Drain and cover the sections with super enhancer for 30 minutes.  
12. Wash in TBS -2 changes for 5 minutes each.  
13. Drain and cover the tissue sections with secondary antibody (HRP-horse raddish 
peroxidise) for 30 minutes.  
14. Wash in TBS -2 changes for 5 minutes each.  
15. Drain and cover the tissue sections with DAB (DiaminoBenzidine) substrate buffer 
for 5-10 minutes (depending on the time suggested in the supplied kit)  
16. Wash in distilled water, counter stained with haematoxylin, clear in xylene and 
mount with DPX.  
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ANNEXURE-IV 
HISTOLOGICAL CLASSIFICATION OF TUMORS OF UTERINE CERVIX-
WHO 
Epithelial tumour 
Squamous tumours and precursors 
Squamous cell carcinoma, not otherwise specified  
Keratinizing  
Non-keratinizing  
Basaloid  
Verrucous  
Warty  
Papillary  
Lymphoepithelioma-like  
 Squamotransitional  
Early invasive (micro invasive) squamous cell carcinoma  
Squamous intraepithelial neoplasia 
Cervical intraepithelial neoplasia (CIN) 3  
Squamous cell carcinoma in situ  
Benign squamous cell lesions 
Condyloma accuminatum 
 Squamous papilloma  
Fibro epithelial polyp 
Glandular tumours and precursors 
Adenocarcinoma  
Mucinous adenocarcinoma 
 Endocervical  
Intestinal  
Signet-ring cell  
Minimal deviation  
Villoglandular  
Endometrioid adenocarcinoma  
Clear cell adenocarcinoma 
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Serous adenocarcinoma  
Mesonephric adenocarcinoma  
Early invasive adenocarcinoma  
Adenocarcinoma in situ  
Glandular dysplasia 
Benign glandular lesions 
Müllerian papilloma 
 Endocervical polyp 
Other epithelial tumours 
Adenosquamous carcinoma  
Glassy cell carcinoma 
Adenoid cystic carcinoma 
Adenoid basal carcinoma  
Neuroendocrine tumours 
Carcinoid  
Atypical carcinoid  
Small cell carcinoma  
 Large cell neuroendocrine carcinoma  
Undifferentiated carcinoma  
Mesenchymal tumours and tumour-like conditions 
Leiomyosarcoma  
Endometrioid stromal sarcoma, low grade  
Undifferentiated endocervical sarcoma  
Sarcoma botryoides  
Alveolar soft part sarcoma  
 Angiosarcoma  
Malignant peripheral nerve sheath tumour  
Leiomyoma  
Genital rhabdomyoma  
Postoperative spindle cell nodule 
Mixed epithelial and mesenchymal tumours 
Carcinosarcoma (malignant müllerian mixed tumour; 
                                                       Metaplastic carcinoma)  
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 Adenosarcoma  
 Wilms tumour  
Adenofibroma  
Adenomyoma  
Melanocytic tumours 
Malignant melanoma  
Blue naevus  
Miscellaneous tumours 
Tumours of germ cell type 
Yolk sac tumour  
Dermoid cyst  
Mature cystic teratoma  
Lymphoid and haematopoietic tumour 
Malignant lymphoma (specify type) 
Leukaemia (specify type) 
Secondary tumours 
 
 
 
 
 
 
 
 
 
 
 
 
135 
 
ANNEXURE-V 
TNM and FIGO classification of carcinoma of the uterine cervix  
Cervical cancer is the only gynaecological cancer that is clinically staged by physical 
examination, chest X-ray, intravenous pyelogram, cystoscopy and proctoscopy. The 
staging of cervical tumours is by the TNM/FIGO classification 
TNM classification 
T – Primary Tumour 
TNM FIGO  
Categories Stages  
TX  Primary tumour cannot be assessed 
T0  No evidence of primary tumour 
Tis 0 Carcinoma in situ (preinvasive carcinoma) 
T1 
 
I 
 
Cervical carcinoma confined to uterus (extension 
to corpus should be disregarded) 
T1a IA Invasive carcinoma diagnosed only by microscopy 
T1a1 
 
IA1 
 
Stromal invasion no greater than 3.0 mm in depth and 7.0 
mm or less in horizontal spread 
T1a2 
 
IA2 
 
Stromal invasion more than 3.0 mm and not more 
than 5.0 mm with a horizontal spread 7.0 mm or less 
T1b 
 
IB 
 
Clinically visible lesion confined to the cervix or 
microscopic lesion greater than T1a2/IA2 
T1b1 
 
IB1 
 
Clinically visible lesion 4.0 cm or less in greatest 
dimension 
T1b2 
 
IB2 
 
Clinically visible lesion more than 4 cm in greatest 
Dimension 
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T2 
 
II 
 
Tumour invades beyond uterus but not to pelvic wall 
or to lower third of the vagina 
T2a IIA Without parametrial invasion 
T2b IIB With parametrial invasion 
T3 
 
 
III 
 
Tumour extends to pelvic wall, involves lower third of 
vagina, or causes hydronephrosis or non-functioning kidney 
T3a 
 
IIIA 
 
Tumour involves lower third of vagina, no extension 
to pelvic wall 
T3b 
 
IIIB 
 
Tumour extends to pelvic wall or causes hydronephrosis 
or non-functioning kidney 
T4 
 
IVA 
 
Tumour invades mucosa of bladder or rectum or extends 
beyond true pelvis 
Note: The presence of bullous oedema is not sufficient to classify a tumour as T4. 
M1 IVB Distant metastasis 
 
N – Regional Lymph Nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
 
M – Distant Metastasis 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
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Stage Grouping 
Stage 0 Tis N0 M0 
Stage IA T1a N0 M0 
Stage IA1 T1a1 N0 M0 
Stage IA2 T1a2 N0 M0 
Stage IB T1b N0 M0 
Stage IB1 T1b1 N0 M0 
Stage IB2 T1b2 N0 M0 
Stage IIA T2a N0 M0 
Stage IIB T2b N0 M0 
Stage IIIA T3a N0 M0 
Stage IIIB T1,T2,T3a 
T3b 
N1  
Any N 
M0 
M0 
Stage IVA T4 Any N M0 
Stage IVB Any T Any N M1 
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